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Executive Summary
One of the challenges in tissue engineering is to have spatial and temporal control over
the biological elements within a scaffold used to guide regeneration including, for example,
transected nerves. Some of the physical and chemical characteristics to regulate regeneration
include incorporation of bioactive domains and release of chemical signals. This study presents
the use of stereolithography (SL) to incorporate localized domains for cell adhesion in addition
to include releasable nerve growth factor (NGF) in the process of building poly(ethylene glycol)
diacrylate (PEGda) hydrogel scaffolds. The capabilities of SL to build finished parts made out of
different materials was shown by building hydrogels composed of inert and biologically dynamic
regions. Bioactive areas consisted of the polymer combined with four amino acids: arginine,
glycine, aspartic acid and serine (RGDS). The RGDS sequence is recognized by cells as an
adhesion signal giving to the PEG substrate the ability to interact biologically. Human dermal
fibroblasts (HDFs) were cultured on top of gels to demonstrate bioactivity of the domains by
anchoring to PEG-RGDS sites. Evidence of control over cell adhesion sites was provided by
HDFs preference to anchor to pre-established domains.

Besides providing sites for cell

attachment, an ideal nerve guidance conduit (NGC) should be able to release growth factors to
promote the axons´ growth. NGF is a neurotrophin known to enhance survival, growth and
differentiation of nerve cells.

The protein was either encapsulated by adding it to the

photocrosslinkable PEGda solution immediately before building the disks or covalently linked
(conjugated) to PEGda. The polymer studied varied in concentration of two molecular weights,
PEGda 3.4 and 6 kDa. PEG hydrogels released the neurotrphin into RPMI-1640 cell culture
medium. An NGF release profile was determined by enzyme-linked immunosorbent assay
(ELISA). Results showed an increased release of NGF over time, ultimately reaching a slow
v

continuous diffusion rate. Protein release rate increased with increasing molecular weight of the
matrix´s mesh and diminished with decreased concentration within the same PEG´s chain size.
Sample materials from PEG 3.4 kDa showed a gradual initial burst while PEG 6 kDa gels
exhibited a marked initial burst release within the first two days of the experiment. The release
profile for disks containing the entrapped protein was measured for at least 7 days. Testing of
the diffused hydrolyzed protein took place up to 30 days from the 20wt% hydrogels, while the
release from PEG 6 kDa was analyzed for 15 days. The total amount of trapped NGF diffused
after one week from PEG 20 wt% 3.4 kDa, 30 wt% 3.4 kDa and 10 %(w/v) 6 kDa was 93±1.9,
46±2ng and 292.23±6.5ng, respectively. Gels with the conjugated protein released 254.6±21.1
from 10% (w/v) PEG 6 k Da matrix and 19.2±0.4 from 20 wt% PEG 3.4 kDa gels after 15 days.
The hydrogels´ supernatants were added to pheochromocytoma (PC-12) cells to demonstrate
NGF bioactivity by observing neurite extension of PC-12 in response to the neurotrophin.
Ultimately, SL was shown to be a promising tool for producing bioactive synthetic PEG guides
for peripheral nerve regeneration.

vi

Table of contents
Page
Acknowledgements ………………………………………………………………. iv
Executive Summary …………………………………………………………….… v
Table of Contents ………………………………………………………………… vii
List of Figures …………………………………………………………………….. ix
List of Tables …………………………………………………………………….... xiii
Chapter 1 ………………………………………………………………………………….. 1
1.0
Introduction ………………………………………………………. 4
1.1
Tissue Engineering ….……………………………….……………. 4
1.2
The Nervous System ………….………………………..………….. 5
1.2.1 Injuries …………………………………………………….. 10
1.2.2 Gaps ………………………………………………………… 10
1.2.3 Solutions ……………………………………………………. 11
1.3 Conduits and Their Characteristics …………..……………………….. 13
1.4 Engineered NGCs: SL as a Building Method …..…………………….. 15
1.5 Chemistry Involved: poly(ethylene glycol) …………………………… 16
1.5.1 1H NMR spectra …………………………………………….. 19
1.6 Biological aspect .………………………..……………......................... 21
1.6.1 Arg-Gly-Asp-Ser (RGDS) …………………………………. 21
1.6.2 Nerve Growth Factor Effect .…………………………….… 21
1.6.3 Cell Lines…...…………………………………………….… 22
Chapter 2 ………………………………………………………………………………….. 23
2.0
Literature Review …………………………………………………. 23
2.1
Biodegradability/porosity ……………………………………......... 23
2.2
Electrical Activity …………………………………………………. 29
2.3
Multilumen Channels ……………………………………………… 30
2.4
Oriented Nerve Substratum ……………………………………….. 31
2.5
Incorporation of Support Cells …………………………………..... 34
2.6
Controlled Release of Growth Factors ……………………………. 36
Chapter 3 ………………………………………………………………………………….. 42
3.1
Materials and Methods ……………………………………………. 42
3.1.1 NGF Release from PEG Hydrogels .……………..………...43
3.1.1.1 PEGda 3.4kDa Photopolymer Solutions …………... 45
3.1.1.2 PEGda 6kDa Photopolymer solutions ……………. 48
3.1.1.3 PEGda stock solutions ……………………………. 49
3.1.1.4 Nerve Growth Factor ……………………………… 49
3.1.1.5 Conjugating PEG-NGF ………………………… 51
3.1.1.6 Photopolymer Solutions Containing NGF ……... 53
3.1.1.7 Stereolithography ……………………………….. 55
3.1.1.7.1 Building in SLA ……………………..... 58
vii

3.1.1.8
3.1.1.9
3.1.1.10
3.1.1.11

3.1.2

3.1.3

6kDa PEG Hydrogels Manufacture ……….….... 61
Lyophilized-Sterilized Hydrogels ……..……….. 65
Time Points ……………………………………... 66
ELISA ………………………………………….. 69
3.1.1.11.1 Remarks About ELISA .………….... 70
3.1.1.11.2 Quantified NGF Released ………… 72
3.1.1.12 PC-12 Bioassay .……………….…..….…………. 74
3.1.1.13 Hydrogels´ Imaging ………….…..……………... 76
PEG Hydrogels with Bioactive Domains ……………….… 77
3.1.2.1 Building in SL …………..……………………….... 77
3.1.2.2 Bioactive PEG Analysis .………………..………… 78
3.1.2.2.1
HDFs Culture ..………………….… 79
3.1.2.2.2
HDFs Seeding ………………..….... 79
3.1.2.3 Hydrogels Fabrication of Compound Materials ….. 79
1
H NMR ………………………………………………….... 80

Chapter 4 ………………………………………………………………………………….. 83
4.0
Results …………………………………………………………….. 83
4.1
Nerve Growth Factor Release……………………………………… 83
4.1.1 Hydrogels´ Imaging ……..………………………………… 84
4.1.2 20 wt% PEG 3.4 kDa …..…………………………………. 87
4.1.3 30 wt% PEG 3.4 kDa ……………………………………… 89
4.1.4 10% (w/v) PEG 6kDa ….………………………………….. 91
4.1.5 NGF Bioactivity …………………………………………… 92
4.2
PEG Bioactive Domains Incorporated by SL………..…………….. 94
4.3
Proton Nuclear Magnetic Resonance …...…………………………. 97
4.3.1 PEGda 3.4 kDa………….……………………………….… 97
4.3.2 PEGda 6 kDa ……………………………………………… 97
Chapter 5 ………………………………………………………………………………….. 102
5.0
Discussion …………………………………………………………. 102
5.1
NGF Release ………………………………………………………. 102
5.2
NGF Bioactivity …………………………………………………… 107
5.3
PEGda Characterizarion ……………………………………………108
Chapter 6 ………………………………………………………………………………….. 102
6.0
Conclusion .………………………................................................... 109
6.1
Future Work …..………………………………………………...… 109
6.2
Recommendations …………………………………………………. 109
Appendix 1 ………………………………………………………………………………… 111
Appendix 2 ………………………………………………………………………………… 120
Appendix 3 ………………………………………………………………………………… 123
Appendix 4 ………………………………………………………………………………… 125
References …………………………………………………………………………………. 129
Curriculum Vita …………………………………………………………………………… 140

viii

List of Figures
Figure 1. 1.

Neuron components [26] ......................................................................................... 5

Figure 1. 2.

Regeneration process in the CNS. Modified from [1,3,28] .................................... 6

Figure 1. 3.

Anatomy of a nerve [25] .......................................................................................... 7

Figure 1. 4.

Macro and micro components of a nerve with respect to a neuron [27] ................. 8

Figure 1. 5

Degeneration followed by regeneration. Adapted from [1,3,28] ........................... 9

Figure 1. 6.

Commercially available products. a) NeuraWrap™ .............................................. 12

Figure 1. 7.

Model of the ideal nerve conduit features [7]. Modified from [1,3] .................... 14

Figure 1. 8.

Chemical structures of a) PEG [52], b) acrylate functional group [64] and
c) PEGda [66] ........................................................................................................ 18

Figure 1. 9.

Proton NMR spectrum of C4H3O10 provided by SDBS [71] ................................. 20

Figure 2. 1.

In vivo results. Histological analysis. Degradation comparison between
the novel PMS versus PLGA after 10 days (left column) and twelve
weeks (right column). Left column scale bar represents 100 µm.
Right column scale bar stands for 200µm. ............................................................ 26

Figure 2. 2.

BAC cells growing over PLGA (left) or PMS (right). Bar = 50µm..................... 26

Figure 2. 3.

Mechanical properties of biomaterials .................................................................. 27

Figure 2. 4.

PC-12 cells unexposed to an electric potential (left) and exposed to 100 mV
(right). Bar scale = 100µm..................................................................................... 29

Figure 2. 5.

Scanning electron micrographs of micropatterned channels. From left to right:
20, 40 and 60 µm apart. Scale bar = 50µm........................................................... 30

Figure 2. 6.

Growth parameters measured. Different angle orientation concerning cell
structure with regards to physical microenvironment ........................................... 30

Figure 2. 7.

Neurite development and orientation within different sized channels. From
left to right: 20, 40 and 60 microchannel in width. Scale bar represents 20µm ... 31

Figure 2. 8.

Nerve cell appearance after cultured in PCL oriented fibers................................. 31

Figure 2. 9.

Live/dead stain on fibroblasts seeded on top of non-functionalized (left) and
functionalized (right) PCL-PEG surfaces .............................................................. 32
ix

Figure 2. 10. Left: Fluorescent image of the hydrogel patterned regions containing RGDS.
Bar = 250µm. ......................................................................................................... 33
Figure 2. 11. SEM image of SCs alignment through the porous architecture. Low
magnification (A). Higher magnification (B). Green: SC.
Ivory: scaffold walls .............................................................................................. 35
Figure 2. 12. Fluorescent stains: blue and green for SC, red for axons. Left: SC supporting
axons. Middle: Scaffold structure. Right: Overlap of the two previous. Cells
aligned within scaffold pores. Scale bar represents 20 µm .................................. 35
Figure 2. 13. Microsphere surface comparison between a) visible porous[99] and b)nonporous[8] ................................................................................................................ 38
Figure 2. 14. Chitosan is reacted with Sulfo-SANPAH to produce a photoreactive species.
Rh is then added to the photoreactive chitosan and exposed to UV light. As a
result, Rh was chemically linked to chitosan ........................................................ 39
Figure 2. 15. Tetramethylrhodamine cadaverine immobilized in concentration step gradients
on chitosan films. Numbers +1 to +5 indicate the number of scans by the laser
over the following pattern. Scale bar = 75 µm ..................................................... 40
Figure 2. 16. NGF conjugated to chitosan films by the use of a laser adapted in a confocal
microscope. NGF control over different figures, areas and concentration was
achieved. Scale bar = 100 µm............................................................................... 40
Figure 3. 1.

Final steps to prepare a sterile photopolymer solution .......................................... 47

Figure 3. 2.

NGF aliquots and their further use. Rectangles resemble
2mL microcentrifuge tubes.................................................................................... 50

Figure 3. 3.

Michael-type addition reaction conditions ............................................................ 52

Figure 3. 4.

Left: Photopolymer solution containing NGF chemically bonded to PEG
3.4 kDa. Right: Photopolymer solution containing the protein free in solution.... 53

Figure 3. 5.

Addition of components to achieve a 10% (w/v) PEGda 6kDa containing NGF
covalently linked (left) and free in solution (right) ............................................... 54

Figure 3. 6.

Modifications to the SLA system. a) SLA model without its original container,
b) base adapted to eelevator platform attached with clay...................................... 56

Figure 3. 7.

Vat on the right is the new modified. Note the reduction of the inner diameter
to reduce the amount of solution required to crosslink one layer.......................... 57

Figure 3. 8.

Inner diameter measurement of the new small container. ..................................... 58
x

Figure 3. 9.

Photopolymer solution being dispensed from a micripipette
into the modified container. ................................................................................... 59

Figure 3. 10. Laser beam (blue spot) passing over the photosensitive solution. ........................ 59
Figure 3. 11. Transfering hydrogels to individual wells of a 24-well plate. ............................... 60
Figure 3. 12. Sport light UV radiation setup. a) Side view, b)front view, c) close-up top view.62
Figure 3. 13. Pipette tip mold to shape circular hydrogels. a) Unsanded pipette tip, b) sanded
pipette tip from its outer diameter, c) measuring the inner diameter. ................... 63
Figure 3. 14. a) Hydrogel extrusion method, b) cured layer without the disks,
thin at the center, c) cured layer thick from the perimeter. ................................... 64
Figure 3. 15. Disks in RPMI-1640. Note the size of the gels versus the
volume of solution in which tNGF is being released. ........................................... 65
Figure 3. 16. a) Retrieving supernatant, b)transferring to 2mL siliconized microcentrifuge
tubes, c) Replenishing hydrogels in wells with RPMI-1640. ................................ 66
Figure 3. 17. a) Individually labeled tubes still in rack, b) samples moved to a case after
labeling and c) labeled case place inside a -20oC freezer. ..................................... 67
Figure 3. 18. Split of retrieved supernatant................................................................................. 68
Figure 3. 19. ELISA plate with samples and standard curve before the addition of 1.0 N HCl.
Note how the samples concentration can be compared with those of the standard
curve according to the color intensity. Standard curve is located at the two last
columns in serial dilutions from top to bottom...................................................... 70
Figure 3. 20. a) Example of standard curve from one of the read plates and ............................. 72
Figure 3. 21. Scanning Electron Microscope used to take high
magnification images of PEG hydrogels. .............................................................. 76
Figure 3. 22. a) and b) are the designs provided created in Solid Works to ultimately
produce c) the final desired hidrogel sketch. Purple sites resemble the areas
where the laser passes scanning............................................................................. 77
Figure 3. 23. Top images (negative and positive) make up the bottom design when they are
overlapped. Purple sites resemble the areas where the laser passes crosslinking
the solution. ........................................................................................................... 80
Figure 3. 24. Poly(ethylene glicol) diacrylate molecular structure. A,a,b and c show the
different hydrogens´ chemical organization in PEGda.......................................... 82
xi

Figure 4.1.

Top view of swollen hydrogels.
Diameter is confirmed to be of 0.5cm as predicted…………………………….. 84

Figure 4.2.

Side view of swollen hydrogels over a glass slide. a) Disks on top of a glass slide
placed at the edge to be able to measure their height, b) measure of the gel width
and c) close up of the measurement. Note that one side of the gel is in fact 1mm
thick, but that height is not even throughout the whole hydrogel diameter…….. 85

Figure 4.3.

Upper: Gold sputtered shrunk (dry) 10% (w/v) PEG 6kDa disk. Down: Noncoated dry gel made of 30 wt% PEG3.4kDa……………………………………. 86

Figure 4.4.

Cumulative NGF release over a seven day period from 20% PEGda 3.4 kDa
hydrogels containing the protein encapsulated (n = 5)………………………….. 87

Figure 4.5.

Cumulative NGF release over a 30 days period from 20% PEGda 3.4 kDa
hydrogels containing the protein conjugated (n ≥ 5)…………………………… 88

Figure 4.6.

NGF release over a 7 day period from 20% PEGda 3.4 kDa sterile hydrogels
containing the protein encapsulated (n = 6)……………………………………. 89

Figure 4.7.

Cumulative NGF release over a seven day period from 30% PEGda 3.4 kDa
hydrogels containing the protein encapsulated (n = 5)…………………………. 90

Figure 4.8.

NGF release from PEG 3.4 kDa hydrogels………………………………………90

Figure 4.9.

Cumulative NGF release over a ten days period from 10% PEGda 6kDa gels
containing the protein encapsulated (n = 4)……………………………………... 91

Figure 4.11.

NGF release from 10 % (w/v) PEG 6 kDa hydrogels…………………….……. 92

Figure 4.10.

Cumulative NGF release over a seven day period from 10% PEG 6 kDa
hydrogels containing the protein conjugated (n = 5)……………………………. 92

Figure 4.12.

Phase contrast images of PC-12 cells exposed to different NGF concentrations.
Magnification is 20X……………………………………………………………. 93

Figure 4.13.

Overlapping the two computer sketches on the left built in SL with different
materials lead to the manufacture of a single part made out of different
components……………………………………………………………………… 94

Figure 4.14.

Original image (up) and the same picture after edited (down)…………………. 95

Figure 4.15.

Top view of HDFs seeded on top of a PEG disk-shaped multi-material hydrogel.
Squares represent the bioactive PEG regions…………………………………… 96

xii

Figure 4.16.

Original 1H NMR spectrum for PEGda 3.4kDa showing the corresponding signal
to specific hydrogen atoms……………………………………………………… 98

Figure 4.17.

1

Figure 4.18.

Original 1H NMR spectrum for PEGda 6 kDa showing the corresponding signal to
specific hydrogen atoms………………………………………………………. 100

Figure 4.19.

1

Figure 5. 1.

Representation of the hydrogel disks accomodation in the SL vat...................... 103

H NMR closer view of PEG 3.4 kDa peaks´ split. Integrated areas are shown in
blue below each signal. Chemical shifts are in green…………………………... 99

H NMR closer view of PEG 6 kDa peaks´ split. Integrated areas are shown in
blue below each signal. Chemical shifts are in green………………………… 101

xiii

List of Tables
Table 1. 1.

Research projects: in vivo animal studies and clinical studies [15] ........................ 4

Table 2. 1.

Peripheral nerve scaffold clinical studies [3] ........................................................ 24

Table 3. 1.

Amount of reagent required according to its desired concentration ...................... 46

Table 3. 2.

Column on the left describes the concentration of solution either in (w/v)
or wt%. Column on the right states the grams of PEGda required per mL
of PBS to achieve the desired concentration provided by the left column ............ 49

Table 3. 3.

Calculations to know the total amount of
NGF released per sample in a 2mL volume. ......................................................... 73

Table 3. 4.

Data management to acquire cumulative values. Numbers on top of columns
refer to the amount of time in hours that the hydrogels were releasing NGF.
Cum refers to the cumulative value which is the summation of the quantified
amount of protein at that time point plus the previous time point value.
Numbers in bold are the plotted mean. In this example n=5 ................................ 74

Table 3. 5.

Solutions given to PC-12s to slowly change their medium from DMEM to
RPMI-1640. Through the different fluid renewals, medium containing
different concentrations of media types were varied until only RPMI-1640
was provided and no DMEM................................................................................. 75

Table 5. 1.

Acylate molar concentration in the solutions involved for hydrogels
fabrication that were used to test NGF release .................................................... 106

xiv

Chapter 1
1.0

Introduction
Different from the central nervous system, the peripheral nervous system has the capacity

to repair itself [1]. This is accomplished through mature neurons that cannot reproduce, but have
the ability to continue growing their axons [2, 3]. When damage to the nerve communication
system occurs, neurotrophic factors that promote axon outgrowth, cell survival, migration and
differentiation are released from the distal end to the proximal nerve stump [4]. Suturing nerve
end to end will bring back tissue continuity. However, it is not the procedure to follow if nerve
elasticity is compromised. A physical guidance is then required for the nerve to find the right
way to enervate the correct target [5]. This is a tube like structure scaffold to be implanted at the
site of injury to mechanically provide support and guide regeneration. Artificial nerve guidance
conduits (NGCs) are being used and investigated for their potential to overcome nerve
discontinuity as an alternative to other grafting methods. Nerve guidance conduits are intended
to have certain characteristics to maximize the enhancement of nerve regeneration.
Unfortunately, the length of 2.5cm is the limit to which successful re-enervation in humans has
taken place with the aid of guidance channels [6]. Today, there are commercially available
NGCs. Still, they are not optimal models as they can be improved towards the ideal NGC.
One of the main characteristics required in a conduit to approach its optimum function is
drug incorporation and release from a predetermined site and at a pre-established rate [7].
Unfortunately, physically entrapped drugs into NGCs are usually diffused from their matrices
very rapidly compared to the time that they are required to be present. To effectively promote
axon outgrowth and hence, nerve regeneration, drug release rates should be slowed to have them
available throughout the healing process [8].
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A second important feature of these guidance cylinders is that the material that they are
made of should have bioactive sites to sustain cell incorporation [7]. The fact that axons align
with respect to support cells makes the addition of these cells into the matrix advantageous
because they conduct the physical way of the axon to follow. Moreover, they secrete growth
factors such as nerve growth factor (NGF).
The object of this project is to modify a material that can be used in nerve scaffolds that
provide chemical and physical guidance for axons to grow along a specific path towards their
goal, the distal stump.
A cell anchorage signal was added to specific sites of poly(ethylene glycol) (PEG) the
polymer that would make up the conduit hydrogel with the purpose of making it bioactive. The
peptide sequence consisted of four amino acids: arginine-glycine-aspartic acid-serine (RGDS).
In addition, the release rate of NGF from its PEG matrix was controlled to provide a diminished
protein diffusion rate. This was accomplished by modulating the scaffold material concentration,
composition, and the neurotrophic factor incorporation technique into the polymer.
Poly(ethylene glycol) is known to have chemical and mechanical tunable properties [9]. As a
synthetic thermoset, PEG has been studied as a photocrosslinkable material for tissue
engineering [10]. Two different studies took place: one to prove modified PEG capable of
sustaining cell adhesion and another to demonstrate that the diffusion of NGF from PEG can be
diminished. Nerve growth factor inclusion consisted on physically trapping the protein into the
scaffold mesh or chemically linking it to PEG before building the scaffolds.
Gelation process consisted of exposing the photocurable solution to ultraviolet (UV) light
of 325nm or 365nm wavelength () depending on the photoinitiator being used. The long
wavelength (λ) source was a UV lamp whereas the short  was produced by a helium-cadmium

2

(He-Cd) laser on a stereolithography (SL) machine. SL is a rapid prototyping method used in the
present work to build hydrogels in a layer by layer fashion. This construction method allows for
consistency in repeatable manufactured elements [11]. However, the use of UV light might
compromise bioactivity of present biological moieties. To demonstrate that this technology can
be employed for tissue engineering purposes, these experiments took place. For the bioactivity
experiment, human dermal fibroblasts (HDFs) were seeded on top of gels containing specific
sites for cell attachment and were analyzed after at 24 and 48 hours to determine if the HDFs
could find bioactive sites for attachment. Regarding the release test, hydrogels were soaked in
solution to release NGF contents by diffusion for entrapped NGF or by hydrolysis of the PEGNGF bond followed by NGF diffusion in the case of covalently bonding the NGF to the polymer.

3

1.1

Tissue Engineering
Tissue engineering (TE) is a relatively new area of research which began in the 1970’s

and started developing in the 1990’s [12]. Literature presents a variety of definitions [2, 12-14].
Ultimately, they all indirectly show TE as an alternative to tissue/organ transplantation. From
this perspective, attention is growing towards TE to overcome the barrier of organs shortage for
transplantation [15].

All these concepts together are directed towards the improvement of

tissue/organ function of many biological systems. Research on TE has been taking place on hard
tissue such as bone regeneration [16], cartilage formation [17], and soft tissue, for example
muscle structure [18], angiogenesis (vascular tissue generation) [19], lung [20] kidney[21] and
nerves [22], among others.

Below is a table that was presented by Cortesini [15] listing

investigations on tissue and organs in vivo and clinical cases regarding tissue engineering. To
know more about the following information, please see reference No.15.

Table 1. 1. Research projects: in vivo animal studies and clinical studies [15]

Tissue
Bladder
Blood vessels
Bone
Cartilage for joints
Ear
Genitals
Heart muscle
Heart valves
Intestine
Joints
Liver
Pancrea s
Meniscus
Peripheral nerves
Salivary glands
Skin
Spinal cord
Trachea
Ureter

In vivo studies
X
X
X

Clinical studies

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
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This thesis work is a contribution to the path of tissue engineering towards improving
peripheral nerve repair.
1.2

The Nervous System
The central nervous system (CNS) and the peripheral nervous system (PNS) make

together the nervous system. The CNS is composed of the brain and spinal cord. Glial cells and
neurons are the main cell type components of the nervous system [23]. Neurons carry chemical
and electrical signals. They have a cell body and extensions called axons or dendrites. Soma is
an alternative name to the cell body, where the cell nucleus is located. Axon hillock is the name
given to the area by which the axon is connected to the cell body. Depending on the direction of
the signal, it is established which is the pre or postsynaptic cell. The presynaptic cell is the
neuron sending information and the postsynaptic neuron is the one receiving the message. The
synapse is the gap that where neurons meet and communicate. Figure 1.1 shows the neuron
components.

Figure 1. 1. Neuron components [26]
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When damage to the communication system occurs at the central nervous system, the
healing process is far from bonding back the same connections present before damage occurred.
The CNS glial cells consist of astrocytes and oligodendrocytes. At the injury site, CNS
glial cells congregate forming a barrier. This obstacle prevents the neuron to connect back to its
previous target by forming scar tissue:

Nerve cell body

Injury

Postsynaptic cell

Astrocyte

Oligodendrocyte

Figure 1. 2. Regeneration process in the CNS. Modified from [1,3,28]

However, neurons in the CNS might find a new path for their dendrites to extend and
form new neuron to neuron connections.
The CNS is connected to the body through the nerves that make up the PNS. This can be
thought as nerves in the PNS being an arrangement of wires sending information to and from the
target organ to and from the brain and spinal cord. Information from the spinal cord and brain to
the rest of the body is carried by efferent (motor) neurons. Impulses from the organs to the CNS
are carried by afferent (sensory) neurons [24]. In the PNS both afferent and efferent neurons are
arranged together within a nerve.

The following picture shows the cross section of a
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neurovascular bundle. It is composed of blood and nerve vessels. It also depicts the basic cell
(neuron) of which a nerve is made of:

Nerve
Neuron

Figure 1. 3. Anatomy of a nerve [25]

The longest extension in a neuron is the axon. The axon is located in the PNS and it is
surrounded by its supportive Schwann cells which are glial cells. Schwann cells make the
myelin sheath that protects, provides support and maintenance for the function of the neuron.
Also, the objective of glial cells in the PNS is to transfer the information of an impulse faster.
In the PNS axons surrounded by their respective Schwann cells are arranged
longitudinally together in bundles called fascicles. At the same time, organized fascicles are
enclosed by connective tissue, the perineurium (peri = around).

The outer structure that

surrounds all the previous is the epineurium.
Going down the structure scale the synapse is found.

It is the region where the

presynaptic neurite releases its chemical signals such as neurotrophic factors. Then, these factors
reach the postsynaptic cell that has specific receptors for them. The following image (Fig. 1.4)
illustrates at various scales the nerve components. At the center two nerve cells interacting are
shown. The left side of the image presents the macroscale structures with respect to the neurons.
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The right part of the figure depicts the microscale regarding a nerve cell, presenting the synaptic
region.

Figure 1. 4. Macro and micro components of a nerve with respect to a neuron [27]

Mature nerve cells lack the capacity for replication. Even though mature neurons cannot
reproduce, they have the ability to continue growing their axons. Therefore, when damage to the
PNS occurs, the proximal end of the nerve has the capacity to regenerate [2].

The axon

development takes place from the proximal (nerve end closer to the spine) to the distal end
(extreme of the nerve more distant from the spine). This happens because signals from the distal
stump are being sent to the proximal to regenerate the nerve.
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As mentioned above, as a consequence of an injury, the distal end will react to the
damage sending signals –such as neurotrophic factors.

Unfortunately, when the axon is

completely interrupted and can have no communication with the soma, the distal end is
degenerated until the body gets rid of it. This process is called Wallerian degeneration, where
macrophages will eat myelin debri.

Nevertheless, degeneration might be followed by

regeneration. Schwann cells with the aid of macrophages and monocytes will support the axon
growth. They will eat debris while protecting and insulating the axon and providing the nutrients
necessary for it to grow [1,3,28]. The process is exemplified in Figure 1.5.

Nerve cell body

Injury

Muscle fibers

Schwann cell

Macrophage

Monocyte

Figure 1. 5. Degeneration followed by regeneration. Adapted from [1,3,28]

Nonetheless, the PNS autonomous repair system may sometimes not be enough, but the
healing process can be enhanced. To accomplish this, tissue engineering is now a growing area
of research with the objective of replacing the function of the damaged tissue and providing a
place for the lost tissue to redevelop. Depending on the type of injury nerves can be crushed
(partially damaged) or totally disconnected.
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1.2.1. Injuries
Damage to a nerve can be the result of a medical condition where part of a nerve has to
be removed or harm due to trauma. For instance, a neuroma –nerve cancer– may develop in a
person. That portion of the damaged nerve has to be taken away leaving a gap of the size of the
segment that was removed. When trauma is the cause of the problem, the outcome can be a
nerve left compressed or discontinued. Consequently, different gap lengths within different
nerve sizes take place, as well as different approaches to repair the injury.
1.2.2

Gaps
The size of the gap is said to be large or small in a relative way. The actual length of this

space between the nerve stumps is very ambiguous. In literature, it is common to encounter
terms of small gaps as “few millimeters” without establishing a defined length. For example,
Bozkurt et al. [22] refer to defects of a small number of millimeters as short without an exact
definition. Others suggest that 1 cm corresponds to a short nerve defect [6]. Different references
define a long space to be considered larger than 2 cm [29], or longer than 0.4 cm [30].
Regardless of the exact definition of a small or long gap, solutions to nerve discontinuity will
depend on the actual size of the injury. Usually a nerve gap described as “small” is when
suturing the proximal and distal ends can be accomplished without compromising elasticity.
Conversely, reference to a nerve discontinuity as “large” is commonly done when a suturing
procedure generates tension.
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1.2.3

Solutions
As stated before, peripheral nerves have the capacity to regenerate by growing their

axons. Nevertheless, they need to be guided to enervate the proper objective to be reached.
Suturing the nerve ends is the preferred procedure over other alternatives when a gap exists [13,
15]. However, if that procedure is not possible to follow, a graft is required to enhance the
healing rate of a long nerve gap [2, 13]. The graft consists of a cylindrical scaffold of open ends
to provide communication between the nerve stumps. The ends of the graft are secured to the
ends of the nerve providing communication between the two stumps. Autografts are the most
widely used guidance conduits. Those are sections of healthy nerves removed from another part
of the body from the same patient that will receive it. The drawbacks of these are that there is a
limited amount of donor tissue, mismatch between the dimensions of the ends of the nerve and
the size of the donor tissue, besides the loss of function from the removed segment. Some other
alternatives are the allograft and xenograft. The first comes from another being of the same
species and the second is tissue from a different species. They will both be rejected by the
receivers’ immune system, the reason why immunosuppressant drugs are required. Moreover,
other tissues such as veins [31, 32] and muscle [32] had been used to serve as a guide for the
nerve to grow over a hollow space that will show the path towards enervating the proper target.
It is important to mention that they show a small degree of success. Even autografts, which are
preferred over all other alternative guidance conduits because of their lack to generate an
immune response, have a high percentage of failure some of them giving rise to the formation of
neuroma [29]. Besides the previously mentioned scaffolds, artificial grafts are being investigated
for their potential to repair nerve discontinuity. These are conduits that can help to bridge the
nerve gap without having to affect a donor site or running out of tissue. Nerve guidance conduits
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(NGCs) are intended to have certain characteristics to maximize the enhancement of nerve
regeneration. Today, there are commercially available NGCs. Still, they are not optimal models.
They are of different materials and different sizes according to the patient’s needs. Some of the
brand names are NeuraWrap™ and NeuraGen® from Integra™, which are collagen based
materials that are biocompatible and bioresorbable [33].

As its name makes reference to,

NeuraWrap™ is a protector for the nerve that is not completely transected.

It wraps the

compressed nerve shielding it from its surroundings. On the other hand, NeuraGen® is a conduit
of varying dimensions from 2 cm to 4 cm in length and 1.5 cm to 7 cm inner diameter, segments
to join nerve ends. A third commercially available is Neurolac®. This conduit is manufactured
by Polyganics B.V. It is a synthetic bioresorbable polyester poly(DL-lactide--caprolactone)
[34]. Their final products are lactic acid and -hydroxyhexanoic acid, which are resorbed by the
body [35].

a)

b)

Figure 1. 6. Commercially available products. a) NeuraWrap ™
from Integra™. Modified from [33]. b) Neurolac ® from Polyganics BV [36]

Even though guidance channels help in the healing process better than no surgical
intervention, they fail to work better than autografts in rats with nerve gaps greater than 10 mm
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[29]. Recently, scientists continue working on finding the optimal conditions and bringing them
together in a scaffold to enhance peripheral nerve regeneration.
1.3

Conduits and Their Characteristics
Mainly six features (remarked next in bold) had been identified as imperative to achieve

the optimum NGC. As of today, there is no conduit that meets all the requirements for the most
advantageous NGC.
The material should be biodegradable. This is, that the body will be able to get rid of it
thorough biological pathways. The advantage of a biodegradable material is that there is no need
for revision surgery. Non-biodegradable scaffolds would have to be removed once the nerve has
healed. The process involves surgical intervention to be taken out, an undesired practice to
follow.

Electrical activity is another component that should be incorporated in a NGC.

Conductivity will stimulate nerve cells to grow. Internal multilumens must also be present. As
of today, only single lumen conduits are available in the market. An intraluminal channel
provides direction and support. Axons tend to grow better here since they have a surface area
where to grow longitudinally. An oriented nerve substratum will account for cell migration.
Best nerve regeneration results had been demonstrated when the previous feature is arranged
having a predesigned orientation. Orientation of the extra cellular matrix (ECM) is advantageous
for the incorporation of support cells.

Glia cells then have guidance to achieve certain

accommodation where their function can be optimized. NGC materials have to be bioactive to
provide a place for cells to adhere. Some materials are naturally bioactive, while others have to
be modified to attain cell adhesion. Last, controlled release of growth factors is a key in a
NGC for enhancing nerve reconstruction. Depending on the type of trauma, the healing time of a
nerve might vary dramatically, for instance days or years. It is imperative that the scaffold
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remains releasing these cues from start to end of the reconstruction process and at the specific
desired site. This leads to the challenge of scaffold building. Its construction should take into
consideration the amount of cues to include and their release rate. as well as their location within
the scaffold to be further released where needed in the nerve, in addition to preserve bioactivity
after signals escape from the matrix.
Next is depicted in Figure 1.7 what illustrates the components that make up the ideal
nerve guidance conduit which will ultimately accelerate the regeneration process:

Controlled Release of
Growth Factors
Incorporation of
Support Cells

Biodegradability/
Porosity

Nerve

Nerve Conduit

Electrical Activity
Intraluminal Channels

Oriented Nerve
Substratum

Figure 1. 7. Model of the ideal nerve conduit features [7]. Modified from [1,3]

All the previous characteristics should be integrated taking into account the wound
healing rate. For example, an ideal scaffold would be worthless if it is absorbed before repair is
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accomplished, or if its component characteristics are not there through the entire healing course.
Reviews with the most recent advancements regarding tissue engineering and NGC are available
[37, 38]
This project presents emphasis on the division of controlled release of growth factors and
a means to incorporation of support cells. Bioactivity of growth factors is required to be present
for months. However, growth factors are usually diffused from their matrix within few days,
promptly losing their effects over the site where they are required. In order to extend their
presence within the healing site, different methods to incorporate them into the conduits has been
used as well as various materials and techniques which will be reviewed in Chapter 2.
Regarding the incorporation of support cells into a NGC, the material of which the conduit is
done has to be bioactive. Either natural, synthetic or hybrid materials should be capable of
interacting with cells. One of the main concerns at the time of manufacturing NGCs out of any
material is if they will preserve activity of their biological domains after the building process.
1.4

Engineered NGCs: SL as a Building Method
The way in which nerve scaffolds are fabricated varies from simple to complex

techniques. Materials often take the shape of the tool where they are placed such as tubular
molds [39, 40]. Unluckily, it is hard to have a precise control over the microstructure. Other
systems such as rapid prototyping (RP) are under investigation to accurately deal with
characteristics, including, for instance, uncommon scaffold shapes, porosity and biological cues
inclusion [41-45]. Rapid prototyping is a set of technologies that produces parts out of powder,
liquids or solids [46]. The achievable complex shapes of end products through RP come from
the beginning of the process. Taking advantage of the accurate capabilities of software sketches,
drawing of the part is created using a computer-aided design (CAD) program. The file design is
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then converted to a compatible mode that can be read by a laser manufacturing machine to be
constructed in three dimensions [43]. The conversion is about slicing the file design so that the
machine builds each slice at a time. It is an additive process in which thin layers are formed at a
time and aggregated one on top of the other until completing the desired structure. In a recent
past, RP was strictly a tool for the manufacture industry. Before proceeding to build a finished
part, a model prototype is commonly manufactured for review before the mass production takes
place. Today, rapid prototyping allows for the execution of these preliminary replicas while
RP´s previous application was restricted to create design models [47]. Recently, it has been
intended to be used with other purposes such as building soft [48] and hard [49] scaffolds as
finished parts. Stereolithography (SL) is under the scope as a suitable and proliferating RP
technique for the creation of tissue engineering scaffolds [50, 51]. SL takes advantage of the
crosslinking ability of some polymeric materials. The apparatus used in this study is equipped
with a helium-cadmium (He-Cd) laser that provides the energy to produce free radicals that
initiate the curing process, in which a liquid solution turns into a solid. This laser exerts a
wavelength (λ) of 325 nm and has a diameter of ~250 µm at the place where it hits the solution
to be gelated, detailed information on this is provided on Section 3.1.1.1. Poly(ethylene glycol)
hydrogels built under this process were investigated to determine if they retain bioactivity of
their incorporated domains (RGDS) and the released nerve growth factor (NGF).
1.5

Chemistry Involved: poly(ethylene glycol)
Poly(ethylene glycol) (PEG) is also known as poly(ethylene oxide) (PEO) depending on

its molecular weight (mw). Usually, people refer to this polyester as PEO when its mw is low
and PEG when its mw is high. Still, this is ambiguous. For example, in a work by Chen et al.
[52], for molecular weights of 400, 1000 and 2000 daltons (Da) is called PEO, while Park et al.
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[53] refer as PEG to this polymer of 570 Da. Here it is called by the name of PEG. This
extensively used polymer has various applications.

Given that natural polymers lack

advantageous attributes that the synthetic ones provide such as photocrosslinking, they are often
modified with PEG. This modification allows the incorporation of functional groups into natural
materials that permit their crosslinking. As a result, physical and chemical properties can be
controlled such as porosity, crosslinking degree, elasticity, swelling behavior and the faculty to
achieve complex shapes [53]. Benefit is taken from PEG’s non-toxic bioinert characteristics as a
cover for other materials to improve their biocompatibility [52]. However, this can also be a
limitation for PEG itself. For example, plain PEG hydrogels are not biodegradable. Despite the
fact that the body cannot get rid of PEG networks, those can be modified with peptides
susceptible of enzymatic attack for their degradation [54], chemically changed with linkages
which bond or dissociate and are pH dependent [55], or copolymerized with poly(lactic acid-coglycolic acid) to not only be bioerodible [56, 57] but to give rise to a biodegradable material
[58,59]. In addition, PEG’s versatility permits the inclusion of molecular moieties such as cell
adhesive peptides for the substratum to become selectively bioactive [60, 61]. As a synthetic
thermoset, PEG has been studied as a photocrosslinkable material for tissue engineering [10, 62,
63]. To accomplish this, PEG is chemically functionalized. Its original hydroxyl reactive end
groups are replaced by different groups. An example is the addition of acrylate end groups,
giving place to poly(ethylene glycol) diacrylate (ACRL-PEG-ACRL or PEGda) [62]. Acrylates
contain vinyl groups (double bonded carbon atoms) linked to a carbonyl carbon [64]. These
functional groups are the ones that allow for the crosslinking process [65]. Afterwards, those
molecules at the ends permit the inclusion of chemical and physical cues that can guide the
axon`s growing path.
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Figure 1. 8. Chemical structures of a) PEG [52], b) acrylate functional group [64] and c) PEGda [66]

The crosslinking process takes place via free radical polymerization. It is induced by the
ultraviolet (UV) light provided by the SL He-Cd laser or by manually providing UV radiation
from a lamp. When the UV light reaches the solution, the photoinitiator reacts (as its name says,
it initiates a process when exposed to certain light). The energy provided by the wavelength to
which the solution is exposed makes the photoinitiator (PI) generate a free radical which starts a
chain polymerization reaction [67]. This free radical is an electron excited from the PI which
attacks a double bond at the ends of the PEGda chain, at its acrylate functional group. Then, as
the double bond is opened, it is ready to react with another opened end of PEGda, and they might
link. When this happens, is when PEGda crosslinks, forming a network. This mesh is the
molecular basis under which PEG hydrogel scaffolds are made of in the present work. Another
important characteristic of PEG is called PEGylation.

This refers to molecules that are

covalently linked to the polymer. Here, a sequence of amino acids was linked to specific sites of
PEG to turn the polymer bioactive. In addition, given that PEGylation makes this food and drug
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administration (FDA) approved polymer a good candidate as a drug carrier [68], NGF was
chemically linked to PEG (PEGylated) besides physically trapped to study its diffusion from the
polymer.
1.5.1

1

H NMR Spectra

A nuclear magnetic resonance (NMR) spectrum is like a finger print of molecules. Each
signal (peak) in the 1H NMR spectrum is formed from hydrogen atoms present in the molecules
of what is being tested and that gives information about the molecule´s chemical organization.
NMR emits radial frequency waves.

Then, electrons around a hydrogen atom induce an

electronic current which provides a local magnetic field. The hydrogen nucleus spins with
(aligned) or against (opposed) the magnetic field exerted by the spectrometer.

The more

hindered a hydrogen atom is, the more energy required to excite it and produce a signal in the
NMR spectrum. Signals appear from left (low field) to right (high field) starting with the least
hindered protons (deshielded) to the more hindered ones (shielded). For example, hydrogen
atoms of tertrametylsilane (CH3)4Si are highly shielded. (CH3)4Si produces a signal high field,
since relatively high energy is required to deshield electrons around its hydrogen atoms and give
a peak. To acquire numerical data, the distance in-between signals with respect to (CH3)4Si is
measured. This is known as the chemical shift (δ). The δ(CH3)4Si = 0.00. Chemical shift of a
signal = distance of peak from (CH3)4Si (in hertz) divided by the spectrometer frequency (in
megahertz) and the resulting δ is reported in parts per million (ppm). To quantify the amount of
hydrogen atoms that make up a signal, the area under the peak can be measured giving ratios
between the different signals. This is known as the “integrated area” and it is used in this work
to calculate the number of repetitive units (n) of PEG in the PEGda used for the experiments
[69].
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Poly(ethylene glycol) diacrylate has four structurally different hydrogen atoms. More
clearly, their difference is according to their configuration within the molecule. For example, the
four hydrogen atoms of the repetitive monomers account for a single signal (their peaks appear at
the same place) in the spectrum since they are chemically equivalent. Hydrogen atoms at the
acrylate end groups lead to three more peaks. Even though hydrogen atoms at the outer carbon
of the vinyl end group look very similar, they are not superimposable mirror images of each
other (not enantiomers), they are diaestereomers of each other. Those hydrogen atoms give rise
to different peaks since they are not equivalent. Registered spectra can be found in databases
such as SDBS. Following is an NMR found for C4H10O3 that corresponds to PEG (without the
acrylate end groups) [71].

Figure 1. 9. Proton NMR spectrum of C 4H3O10 provided by SDBS [71]
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1.6

Biological Aspect
The material of which nerve scaffolds are made of should be able to support biological

activities as mentioned in Section 1.3. However, secondary effects such as immune rejection
must be avoided. Due to the fact that PEG causes no response by its host, it makes it a good
implantable hydrogel material candidate. PEG can be then combined with chemical moieties
that exert specific responses in cells without causing undesired consequences.
1.6.1

Arg-Gly-Asp-Ser (RGDS)
Arginine, glycine, aspartic acid and serine (Arg-Gly-Asp-Ser or RGDS) make up a

sequence recognized by cells as a signal for attachment. Since PEG is intrinsically non-cell
adherent, the RGDS sequence PEGylated to it turned the hydrogel capable of interacting with
cells. PEG has previously been linked to this tetrapeptide and hydrogels have been patterned
with this material [61]. Incorporation of this oligopeptide contributes to the enhancement of
nerve regeneration by providing sites on PEG hydrogels for cell adhesion.
1.6.2

Nerve Growth Factor Effect
Nerve growth factor belongs to a family of neurotrophins and it is the best known of them

[71]. Its whole complex known as 7S NGF (S being the sedimentation coefficient) is composed
of three subunits (α, β and γ). The β-NGF subunit is referred as responsible for the protein
activity [72] through the high affinity receptor, tyrosine kynase A (TrkA). However, it has been
shown that 7S NGF has different activity than 2.5S NGF in vitro [73]. Even though the terms βNGF and 2.5S NGF are used interchangeably for having identical activities, differences as their
preparation have been stated [74].

After its discovery [75] and isolation from the mouse

submaxilary glands and snake venom [76], it was known for having specific growth effect on
chick embryo nerve cells [77]. It was then known for its potential on regenerating gaps across
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nerves [78]. NGF promotes cell growth, survival and differentiation, reason why it is a potential
protein to incorporate in nerve guidance conduits to accelerate the nerve regeneration process.
1.6.3

Cell Lines
Culturing cells is a process where cells grow and proliferate in vitro; this is, in the

laboratory. This is advantageous because we can have controlled conditions and specifically see
the behavior of these as a consequence of a known change. Depending on the type of study that
is being made and what is to be determined is the cell line to be used. In this case, human dermal
fibroblasts (HDFs) were used to test the bioactivity of the adhesion ligands on PEG after their
presence during the gels manufacture by rapid prototyping. HDFs were chosen for their easiness
to culture. HDFs can be cultured over a surface evenly dispersed. They tend to align with each
other once they reach a high confluency. HDFs are a finite cell line (derived directly from
tissue) and they are better to be used before passage 14. On the other hand, pheochromocytoma
(PC-12) cells are an infinite cell line derived from an adrenal gland tumor in a male rat. They
tend to grow in colonies forming cell aggregates (or clumps). PC-12s mimic nerve cells. They
tend to extend processes when exposed to NGF. For this reason, pheocrhomocytoma cells were
chosen to test the bioactivity of NGF after the process of this protein inclusion into the hydrogels
and its release from the PEG´s mesh. Different cells require different culture techniques and
those are described in Chapter. 3 Materials and Methods, Sections 3.1.1.11.3 and 3.1.2.2.1.
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Chapter 2
2.0

Literature Review
This chapter provides an overview of what other researchers have accomplished

regarding the development of conduit scaffolds for peripheral nerve repair.

The section

describes their methods and how their work contributes towards achieving the ideal nerve
guidance conduit (NGC). By ideal, the description according to Hudson et al. [7] as mentioned
in Chapter 1 is followed. Specific attention is given to the division of “controlled release of
growth factors” since it is the fraction intended to be improved by this thesis work, one of the
elemental characteristics required on a NGC.
2.1

Biodegradability/Porosity
After reviewing the various aspects of tissue engineering for nerve repair, Huang et al. [3]

presented a chitosan and poly(D,L-lactide-co-glycolide) (PLGA) scaffold as a nerve graft with
intraluminal channels.

It is a combination of a natural and a synthetic polymer, both

biodegradable. Chitosan is a polysaccharide found in many animals (crustaceans´ shell, insects
and fungi cell walls) and it is vastly available [79].

PLGA is a copolymer composed of

poly(glycolic acid) (PGA) and poly(lactic acid) (PLA). These two polymers by themselves
reveal different characteristics in contrast to the exerted properties when they are combined.
Together, as PLGA the copolymer provides the mechanical strength and cell adhesion properties
that chitosan lacks [80]. Moreover, Huang et al. [3] describe their conduit building technology
as an easy and repeatable process. Multichannels are formed within the scaffold. Lyophilization
provided the porosity required and nickel-chromium (Ni-Cr) wires were used to form the lumens.
These internal channels were consistent in diameter throughout the scaffold, measuring 115 m
wide.
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In addition, these researchers gathered and published data provided by different
investigators and it is presented next. The following table lists different polymers, copolymers,
natural and synthetic materials that have been utilized in the fabrication NGCs. It is shown in
which animals were implanted for their study and the gap length of nerve the graft attempted to
bridge. All of the following are bioresorbable materials. Table 2.1 is found interesting because
it shows not only natural materials, but also synthetic ones that are important for resembling
characteristics of the natural ones, such as biodegradation.

Table 2. 1. Peripheral nerve scaffold clinical studies [3]

Material
Chitosan
Collagen

Animal
Rat
Rat
Rat
Gelatin
Rat
Polyglycolic acid (PGA)
Monkey
Rat
Human
Rabbit
Polyglactin
Rabbit
Poly(organo)phosphazene
Rat
Glycolide trimethylene carbonate
Rat
Polyurethane
Rat
Methacrylate-based hydrogels
Rat
Poly 3-hydroxybutyrate
Rabbit
PLGA
Rat
Rat
Poly(L-lactide-co-caprolactone)
Rat
PGA mesh coated with collagen
Dog
Poly(glycosaminoglycan-co-collagen)
Rat
Poly(L-lactide-co--caprolactone)(inner): a mixture Rat
of polyurethane and polylactic acid (outer)

Gap length (mm)
15
30
12
10
1-1.5
5
5-30
30
20
10
5
8
10
2-4 cm
12
4
10
80
15
7

Talking of non natural materials, Bruggeman et al. [81] developed a family of
biodegradable poly(polyol sebacate) (PPS) polymers by reacting polyols with sebacic acid.
Xylitol, sorbitol, mannitol and maltitol polymers were reacted in different ratios with sebacic
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acid, giving rise to poly(xylitol sebacate) (PXS), poly(sorbitol sebacate) (PSS), poly(mannitol
sebacate) (PMS) and poly(maltitol sebacate) (PMtS). Ratios between the polyol and sebacic
acid were PXS 1:1 and 1:2, PSS 1:1 and 1:2, PMS 1:1 and1:2, and a 1:4 stoichiometry for PMtS.
Physical and mechanical properties of these biodegradable materials were measured such
as contact angle, young’s modulus, tensile stress, elongation, glass transition temperature,
density and molecular weight.
These synthetic polymers were compared to poly(L-lactic-co-glycolic acid) PLGA, a
widely known and used copolymer for its biocompatibility and medical applications. Nuclear
magnetic resonance (NMR), gel permeation chromatography (GPC) and an Instron® 5542 were
required for the prepolymer characterization and fourier transform infrared spectroscopy (FTIR)
to evaluate after crosslink. Poly(polyol sebacate) polymers went through in vivo and in vitro
analysis. PPS disks of 10 mm diameter and 1 mm height were implanted in rats to test for
biocompatibility and biodegradation. Results showed PPS mass loss in all implanted polymers at
different time points. PSS in a 1:1 ratio was completely degraded by the time of twelve weeks.
However, cells would not attach to this stage.

Images below show the in vivo results of

histological analysis. Figure 2.1 involves PMS 1:2 implanted after ten days and twelve weeks as
compared to PLGA. The column on the left presents pictures of the polymers after 10 days of
implantation, whereas the right column shows the panorama after twelve weeks. Muscle is
separated from the polymer by the fibrous capsule (C). Label depicts the polymer name and its
ratio composition.
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Figure 2. 1. In vivo results. Histological analysis. Degradation
comparison between the novel PMS versus PLGA after 10 days (left
column) and twelve weeks (right column). Left column scale bar
represents 100 µm. Right column scale bar stands for 200 µm.
M= muscle, C=fibrous capsule [81]

For the in vitro studies, different primary and cell lines were grown over surfaces of PPS
polymers. For instance, BAC cells were cultivated over PLGA and on a PMS surface. In
comparison, cells on both surfaces present the same morphology, even though they are unequal
in population number. Following is an illustration (Fig. 2.2) of BAC cells cultivated over PLGA
(left) and PMS (right).

Figure 2. 2. BAC cells growing over PLGA (left) or PMS (right).
Bar = 50µm [81]
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Mano et al. [82] dedicated to analyze biopolymeric materials for hard tissue replacement,
bone and cartilage. Only starch and starch based materials were studied here. They studied
biocompatible materials to be inside the body for a limited amount of time or to remain there
indefinitely. For this objective, they analyzed bioinert non degradable and degradable polymers.
The following image (Figure 2.3) depicts a graph of the mechanical properties of
polymeric, biological, ceramic and metallic materials with biomedical applications. The interest
in showing this graph is to make the point that if these are mixed, they can give rise to composite
materials that provide combined properties according to the needs.

These might be of

importance if an implant is intended to partially degrade, while part of it might be necessary to
stay permanently, for example. Then, a composite material might be chosen based on its
components´ properties.

Figure 2. 3. Mechanical properties of biomaterials [82]
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To have control over the biodegradability rates, materials might be combined to find the
best degradation rates [83]. Besides the biodegradability of the material, the method of scaffold
construction is important in order to have control over certain features such as the physical
structure. Pierucci et al. [84] proposed a solvent evaporation membrane preparation method of
known biodegradable polymers. Poly (L-lactic acid) (PLLA) and poly(caprolactone) (PCL) 300
and 100 kDa mw, respectively, were the materials under investigation. Membranes for the
conduits were built by this solvent evaporation novelty process and through the extrusion method
to compare their efficacy in the regeneration process. Some of the advantages mentioned of
using this process were the easiness to manage the conduit when interacting with the nerve
regarding suture, resistance and flexibility.
One of the important aspects of biodegradable materials is their porosity. This plays an
important role regarding degradation rates and growth factors delivery. Access to nutrients,
surface area and redistribution of cells throughout the scaffold are mentioned to be affected by
the pores´ size and pores´ distribution.

More control over the mentioned features can be

achieved if porosity is previously structurally organized. The methods of material fabrication for
the scaffold are often responsible for the porosity outcome. Capes et al. [85] proposed the use of
sugar spheres of different diameters to generate the desired porosity. A method for calculating
numerically how is the surface area of the scaffold affected by the size of the sphere is provided
by their study.
In a different investigation, a biodegradable material made of polylactic acid (PLA) and
calcium phosphate glass was surface characterized by Chales-Harris et al. [86]. For the scaffold
preparation chloroform and dioxane were the two solvents used for solvent casting or phaseseparation method. Different results were acquired regarding chemical and physical properties
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such as surface morphology, roughness, wettability and the material´s capacity for protein
adsorption.
2.2

Electrical Activity
A conductive polymer was developed by Schmidt et al. [87]. Oxidized polypyrrole (PP)

was the film over which pheochromocytoma (PC-12) cells were grown to test for a response to a
100 mV voltage. PC-12 cells were differentiated with 25 ng/ml nerve growth factor (NGF).
Once cells extended neurites, they were exposed to electrical activity. Cells responded to the
treatment by elongating their neurites. This paper is a good reference for the present thesis
regarding materials and methods. Cells were seeded at 1.33 x 104 cells/cm2. PC-12 cells were
maintained with DMEM and 25 ng/mL NGF. Subsequently, 10 – 20 images were taken per well
going up to down and left to right. Additionally, it is mentioned that a well measures 1 cm x 1.5
cm from the inside. Figure 2-4 shows the cell response to no electric potential or to 100 mV one
day after electrical stimulation through the PP film.

Figure 2. 4. PC-12 cells unexposed to an electric potential (left) and
exposed to 100 mV (right). Bar scale = 100 µm [87]

In vivo studies also took place in this experiment. PP film was implanted in rats as well
as a PLGA film for their comparison. After two weeks, PP showed less immunologic response
than PLGA, demonstrating its relative bioinactivity.
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2.3

Multilumen channels
As the result of providing multichannels for neuron like cells to grow, Mahoney et al.

[88] were able to influence PC-12 development orientation by providing a physical cue.
Different sized polyimide microchannels were built over glass slides and coated with collagen
(Fig. 2.5) for further adhesion of pheochromocytoma (PC-12) cells.

Figure 2. 5. Scanning electron micrographs of micropatterned channels. From left to
right: 20, 40 and 60 µm apart. Scale bar = 50µm [88].

For the analysis of cell structure within the channels, angles were measured as follows:

Figure 2. 6. Growth parameters measured. Different angle orientation
concerning cell structure with regards to physical microenvironment [88].

It was found that cells cultured in microchannels extended less, but longer neurites than
without a channel regardless the channel width.

Interestingly, it was noticed that neurites

directed themselves parallel to the channel wall if these cell processes came into contact with a
channel wall (Figure 2.7).
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Figure 2. 7. Neurite development and orientation within different sized channels. From left to
right: 20, 40 and 60 microchannel in width. Scale bar represents 20µm [88].

2.4

Oriented Nerve Substratum
Orientation of the extracellular matrix (ECM) is important because it dictates cells a path

to follow when growing. Ghasemi-Mobarakeh et al. [89] aligned fibers composed of different
ratios of poly(ε-caprolactone) (PCL) and gelatin. Rat nerve stem cells (C17.2 cells) were grown
over the aligned matrix to observe their proliferation. Scanning electron micrographs show
evidence the alignment of cells with respect to the fibers´ orientation (Fig. 2.8)

Figure 2. 8. Nerve cell appearance after cultured
in PCL oriented fibers [89].
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Cells will follow not only a physically patterned trail, but also chemical indications of
where to adhere that will lead to an oriented cell growth.
Advantage has been taken from the fact that cells will only adhere to places where they
find a particular sequence of amino acids.

Glycine-Arginine-Glysine-Aspartic acid-Serine

(GRGDS), a signal for cell attachment was included in a polymeric mesh. Grafahrend et al. [90]
produced blocks composed of a combination of polymers. Poly(ethylene glycol) (PEG) and
poly(-caprolactone) (PCL) were the basic units composing the block.

While PCL is

biodegradable and hydrophobic, PEG is the hydrophilic part where the pentapeptide was linked
to. Human dermal fibroblasts were used to verify that cell adhesion will be present only where
GRGDS was incorporated. The scientific paper names this surfaces as functionalized or nonfunctionalized depending if they are bioactive or not, respectively. Fluorescent images were
taken with a live/dead stain on fibroblasts to analyze cell adhesion. It was shown that cells
attached only were to the GRGDS-PEG-PCL surface and not to the PEG-PCL region missing the
oligomer.

Figure 2. 9. Live/dead stain on fibroblasts seeded on top of non-functionalized
(left) and functionalized (right) PCL-PEG surfaces [90].
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A similar study performed by Hahn et al. [61] permitted the interaction of human dermal
fibroblasts (HDFs) with poly(ethylene glycol) (PEG) hydrogels´ regions targeted with a
tetrapeptide. The amino acid sequence was RGDS which information is given in Chapter 1,
Section 1.6.1. The technology used in this experiment was simple and the instruments included
every-day tools: software (Photoshop®) and a laser-jet printer to acquire the masks and desired
sketches. PEG hydrogels with the peptides sequence domains were identified by florescent
images to make them evident to sight. Moreover, HDFs were seeded on top of the hydrogels
containing RGDS domains and attached only to those given adhesion sites (Fig. 2.10).

Figure 2. 10. Left: Fluorescent image of the hydrogel patterned regions containing RGDS.
Bar = 250µm [61].

As stated before, a cell substratum that contains physical orientation and provides
chemical guidance is important since a path is predetermined and given to cells for their growth.
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2.5

Incorporation of Support Cells
The incorporation of Schwann cells (SC) into nerve grafts is a key for reestablishing

nerve function. Glial cells provide signals for growth and survival to the regenerating axons
such as neurotrophins. Tabesh et al. [91] were given to the task of reviewing materials that could
support Schwann cells addition.

Interestingly, in this review article it is mentioned that

regarding cell inclusion within a scaffold might be better to have cells other than SC, but that
behave like them. The reason mentioned is that SC from the patient would have to be harvested
from another nerve. This will comprise the donor´s function. To this thesis concern, they
reviewed a variety of the most widely used natural and synthetic polymers for nerve scaffold
manufacture. Collagen, chitosan, agarose and fibronectin were the natural materials studied.
Poly(D,L-lactic acid), poly(lactic-co-glycolic acid), poly-β-hydroxybutyrate, poly-ε-caprolactone,
polypyrroles, poly(ethylene glycol), poly(glycerol sebacic acid), and poly(2-hydroxyethyl
methacrylate) were the synthetic materials under review.

As a result of their study, they

proposed a material which composition was a combination of a natural and a synthetic polymer.
As an example the combination of poly-ε-caprolactone and collagen was given. Their outcome
was based on the polymers´ mechanical and chemical properties that are enhanced when brought
together.
Bozkurt et al. [22] isolated Schwann cells from the sciatic nerve of ten Lewis rats and
cultivated them. Further on, SCs were seeded into 2D and 3D collagen (type I) scaffolds. Cell
migration within 3D cylinders was measured at 3, 7 and 14 days. Graft dimensions were 1 cm
long and 2 mm in diameter. Interconnected pores and channels were made by a directional
freeze drying technique. SCs aligned themselves throughout the channels of porosity along the
collagen nerve graft (Figure 2.11).
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Figure 2. 11. SEM image of SCs alignment through the porous
architecture. Low magnification (A). Higher magnification (B). Green: SC.
Ivory: scaffold walls [22].

Additionally, collagen scaffolds containing SCs were loaded with hemisected dorsal root
ganglia (DRG). The purpose was to observe if neurite extension would be guided and supported
by SCs. Indeed, the following picture (Fig. 2.12) shows in red an axon behind a Schwann cell.

Figure 2. 12. Fluorescent stains: blue and green for SC, red for
axons. Left: SC supporting axons. Middle: Scaffold structure.
Right: Overlap of the two previous. Cells aligned within scaffold
pores. Scale bar represents 20 µm [22].
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Schwann cells are known to have influence over nerve regeneration by not only
physically guiding axon elongation, but providing chemical signals as secreting nerve growth
factor [92, 93]. As an NGF source, SCs are good candidates to be incorporated into nerve
scaffolds to contribute as an NGF provider to accelerate regeneration. However, large numbers
of these cells are required and it is not feasible to have them ready at the time they are needed
since they have to be cultured from the host that will receive them to suppress response by the
immune system. An alternative being studied is the substitution of SCs for other ones that mimic
their function such as transected HEK-293 cells [94]. Cells as the only supply of NGF are not
sufficient and this protein source should come from somewhere else such as the scaffold itself.
Moreover, its release has to be controlled to ensure activity over the specific desired site.
2.6

Controlled Release of Growth Factors
Controlled release of growth factors is object of the present investigation. Even though

tubulization helps to avoid diffusion of chemical cues from the site where they are required [95],
there is also a need to make drugs available from the various scaffold materials either anchored
to the source or entrapped to be released. Our work is based on the following methods and can
be compared to them, having in mind that our specific drug and material is nerve growth factor
(NGF) within poly(ethylene glycol) (PEG). Detailed reviews describe strategies that have or
have not been applied to generate physical and/or chemical gradients. Within those reviews,
tables are presented summarizing the work of different researchers. Given data is regarding their
methods, incorporated cues, substrates, kind of cells for analytical purposes besides information
about polymers and their release capabilities [96, 97]
To have control over the release rate of chemical signals is a challenge. Many methods
are under investigation to achieve gradients of different cues. Some experiments have already
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gone in vivo to test the performance of grafts in regenerating rat sciatic nerve. Even though
results were satisfactory, they were not ideal and research has to undergo further [30]. Recently,
it has been shown that consciously managing biodegradability rate and porosity of the substrate
are suitable ways to have a predetermined influence over drug delivery [98]. In addition, the
incorporation of microparticles as drug carriers into scaffolds has shown to be a feasible drug
delivery method [99]. For example, Cao and Shoichet [83] investigated the release of a protein
from PCL or PCL/PLGA microspheres. Their reason to use a combination of biomaterials was
to find the best microspheres´ degradation rate for protein delivery. Ovalbumin (OVA) was used
instead of NGF due to their similar molecular weight and thus, comparable release behavior from
the matrix. Their analysis was done over 91 days.
NGF release from silk fibroin matrices has been accomplished for 3 weeks [100].
Microspheres made of poly(D,L-lactide-co-glycolide) (PLGA) has also been addressed for
encapsulation of NGF. Growth factor diffusion from these particles was observed from different
ratios of PLGA components with and without NaCl (salt) to obtain data regarding the best
parameters for NGF inclusion and release control. They noticed that salt had an adverse effect
on the neurotrophin, although it reduced the unwanted initial high dose release of protein. NGF
release was quantified up to 91 days by radioactivity counting. Moreover, NGF that left the
samples after one day without salt continued bioactive after the loading and diffusion process as
shown by a pheochromocytoma (PC-12) cell bioassay [101]. While these microspheres were
porous, other experiments that include the use of non porous (at least non visible) microspheres
decreased substantially the leaching of the neurotrophin. This can be considered both positive
and negative, as the initial burst release was diminished, but very few of the protein diffused
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below the concentration required. And even though small, this system allowed for at least 70
day diffusion time. [8].

Figure 2. 13. Microsphere surface comparison between a) visible porous [101] and b) nonporous[8]

Besides microsphers, other microstructures are promoted as drug carriers, such as
microtubules. Agarose hydrogels with lipid microtubules and lipid microtubules themselves
have been examined as vehicles for different molecular weight proteins delivery. With the aid of
a PC-12 bioassay, results revealed that after the manufacturing process protein bioactivity is
preserved. In addition, bovine aortic smooth muscle cells were not affected negatively, showing
that the process is cytocompatible. Findings were also that the higher the molecular weight of
the protein, the less its release rate [102].
Diffusion rate has also tried to be controlled by relatively weak chemical interactions.
Such is the case of affinity based systems for NGF release. In this case, proteins are attracted
more or less to certain domains within their matrix, staying with it or leaving it [103,104].
Hydrogel materials do not necessarily contain drugs within a carrier. The scaffold itself
can be a source of protein without any additives [105]. The protein is then available free from its
source after diffusion or anchored to a surface.
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A study by Yu et al. [106] revealed that NGF can be provided immobilized from a natural
source. Chitosan (mw. 25,000 g/mol) films were chemically combined with collagen to further
enhance cell attachment. Films were then linked to sulfo-SANPAH, a reagent that would make
chitosan photocrosslinkable.

Then, tetramethylrhodamine cadaverine (Rh) which resembles

NGF in this study was bonded to chitosan to further create a gradient over the films. This was
accomplished by exposing specific regions to UV light. The light source ( = 364 nm) was
coming from a laser adapted to the confocal microscope and the pattern was designed
manipulating the microscope´s software. A concentration gradient of a NGF-like reagent was
achieved utilizing the accuracy of the confocal microscope. Next, it is structurally shown how
Rh was covalently bonded to chitosan. It is clearly seen how an amine group from chitosan is
bonded to a carboxyl group in sulfo-SANPAH (Figure 2.14).

Chitosan

Sulfo-SANPAH

Tetramethylrhodamine Cadaverine

Figure 2. 14. Chitosan is reacted with Sulfo-SANPAH to produce a photoreactive species. Rh is then added to
the photoreactive chitosan and exposed to UV light. As a result, Rh was chemically l inked to chitosan [106].
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Because of its primary amine groups, Rh resembles NGF in this experiment. With the
previous steps, a concentration gradient of Rh over the chitosan films was achieved. The stage
movement was controlled as well as the UV exposure or laser scans. Figure 2.15 shows an
increasing concentration of Rh immobilized as the number of scans was increased from left to
right.

Figure 2. 15. Tetramethylrhodamine cadaverine immobilized in concentration step
gradients on chitosan films. Numbers +1 to +5 indicate the number of scans by the
laser over the following pattern. Scale bar = 75 µm [106].

Moreover, NGF was studied over these films to immobilize it on specific sites and with a
specific shape. Also, NGF was conjugated to demonstrate that the same chemistry used to link
Rh can be used with this protein.

Figure 2. 16. NGF conjugated to chitosan films by the use of a laser
adapted in a confocal microscope. NGF control over different figures,
areas and concentration was achieved. Scale bar = 100 µm [106].

Nerve growth factor was not released into solution once immobilized, but it was made
available to superior cervical ganglia (SCG) neurons. Yu et al. [106] were able to show that
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NGF was bioactive after the linking process, since SCG neurons extended processes when grown
over surfaces containing immobilized NGF.
Similar to the previous mentioned research, Kapur and Shoichet [107] also developed a
method to link NGF covalently to a surface and created gradients of this growth factor.
Poly(allylamine) (PAA) is the photoreactive material that was placed on top of poly(2hydroxyethylmethacrylate) (PHEMA) gels, as PAA provides a site for cell attachment and it is
the polymer to which NGF was immobilized. In comparison to our work, disks were fabricated
and divided into two groups. In contrast to our study, they tested the amount of NGF bound to
the surface and its bioactivity. Group 1 was analyzed by a direct enzyme-linked immunosorbent
assay (ELISA) and disks from group 2 were plated with PC-12 cells to see if they responded to
the growth factor by extending processes. The disks´ dimensions were 0.5 mm in diameter to fit
into wells of a 96-well plate and the cell density was 7x104 cells/disk. The information provided
in this study demonstrated that NGF can in fact be bonded to PHEMA-PAA gels while
maintaining the protein´s bioactivity.
As stated before, biodegradability of materials is one of the properties that permit to
control the diffusion of a protein if the degradation rate is managed. Biodegradability can be
driven by several factors, such as bonding formation or dissociation according to the
environment’s pH. PEG has been widely studied as a drug transporter. PEG has been modified
with schiff base linkages which make the hydrogel biodegradable. These are bonds that respond
to pH changes, leading to release the hydrogel´s contents as it degrades when bonds are broken
[55]. To our interest, PEG has been studied for drug release by itself [108]. However, it has also
been explored in combination with other materials to take advantage of biodegradability and
have better control over drug delivery [57, 109, 110].
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Chapter 3
3.1

Materials and Methods
Turning inert materials bioactive and controlling the release of growth factors has been

accomplished using a variety of materials and techniques as mentioned in Chapter 2, Literature
Review.

In one experiment hydrogel disks were built as a sample of the complete nerve

guidance conduit (NGC) material to analyze the neurotrophin release from them. The matrices
under investigation here are two molecular weights (mw) of the same polymer: poly(ethylene
glycol) diacrylate (PEGda) mw 3.4 kDa amd 6 kDa. The polymeric material of the lower
molecular weight (mw) was photocrosslinked in a stereolithography (SL) machine with the aid
of Irgacure® 2959 (Ciba®) (I-2959) as the photoinitiator (PI) and the material of higher mw was
crosslinked utilizing a UV lamp spot light setup and 2,2-dimethyl-2-phenyl-acetophenone
(DMPA) as the PI. Protein incorporation was approached in two ways: physically trapped and
chemically conjugated for their comparison. First, the protein solution was combined with the
photopolymer solution immediately before the crosslinking process.

In this setup the

encapsulated neurotrophin (nerve growth factor, NGF) release expectations were that the
physically incorporated NGF would come out in a relatively short time frame (faster) compared
to the second incorporation method. The other method of inclusion was conjugating (chemically
bonding) NGF to PEG in a releasable manner. In this way, PEG and NGF form a covalent
hydrolysable bond expected to break under physiological conditions, leaving NGF free to move
and diffuse out from its matrix.
To test if SL is a good technique to build bioactive PEG scaffolds, a different experiment
took place. Hydrogels of different materials (bioactive and inert PEG) were manufactured with
another team member of the tissue engineering research group. The mw of the polymer was 3.4
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kDa and solutions contained a 20 wt% PEGda concentration. For all experiments, chemical
reagents were supplied from Sigma-Aldrich, St Louis, MO unless otherwise stated. Water
supply came from a reverse osmosis ultrapure water system (arium® 611VF, Sartorius).
3.1.1

NGF Release from PEG Hydrogels.
Wells of Costar® flat bottom 24-well plates (TC-Treated Microplates, Corning Inc.) were

filled with 2mL of RPMI-1640 medium per well and left one day inside the incubator before
proceeding with the study. Conditions within the Shel Lab® incubator (CO2 Series Sheldon Mfg.
Inc.) were 90% humidity and 5% CO2. In addition, materials to be used such as pipette tips,
amber vials and microcentrifuge tubes were sterilized autoclaved (MLS-3750, Sanyo Electric
Co., Ltd., Japan) at 121 oC for a 20 min cycle. Stock solutions recipes are presented next.
Phosphate buffered saline (PBS):
PBS is an isotonic solution and as a buffer it counteracts for changes in pH, making
solutions to be stable. Isotonic refers to a solution that has similar electrolytes than those in the
physiological environment of cells. Thus, when cells are in contact with this solution, little or no
water will come in or out due to difference in ionic concentration, avoiding dehydration of the
cell or too much water intake that would make the cell literally to explode.
- 0.256 g Sodium phosphate monobasic monohydrate (NaH2PO4·H2O)
- 1.190 g Sodium phosphate dibasic, anhydrate (Na2HPO4)
- 8.75 g Sodium chloride (NaCl)
- Volume was filled up to 1 L with ultrapure water
- pH = 7.43 adjusted with 1.0 N HCl or 1.0 N NaOH
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Hydrochloric acid 1.0 N:
Acid was added to water inside a fume hood. As a safety rule, acid is always added to water.
This is an exothermic reaction (heat is produced), but heat is rapidly absorbed by water. If water
is added to the acid, an accident can occur.
-

Transferred 8.3 mL of 12 N HCl into a 100 mL volumetric flask.

-

Filled up with ultrapure water to complete 100mL

-

The meniscus was above the flask neck´s mark.

Sodium hydroxide:
Sodium hydroxide (NaOH) was opened the minimum possible.

For example, while

weighing, the NaOH container remained closed to avoid moisture from the environment to come
into contact with the sodium hydroxide pearls.
Two different solutions of varying concentrations of NaOH were prepared: 1.0 N and 10 N.
If not familiar with the solution to which pH was going to be adjusted, 1.0 N was used to raise
pH. For known solutions whose pH is hard to raise (less than 0.01 units per drop of 1.0 N base)
the highly concentrated (10 N NaOH) was employed.
1.0 N NaOH solution:
-

Weighted 4g (container was opened the minimum possible to avoid moisture into NaOH)

-

Transferred to a 100 mL volumetric flask and added ultrapure water up to 100 mL.
10 N NaOH solution:

-

Weighted 4g (container was opened the minimum possible to avoid moisture into NaOH)

-

Transferred to a 15 mL graduated cylinder flask and added ultrapure water up to 10 mL.

44

3.1.1.1

PEGda 3.4kDa Photopolymer solutions
Prepolymer solutions were prepared from poly(ethylene glycol) diacrylate 3.4 kDa

(Aclylate-PEG-Acrlylate MW 3400, Laysan Bio, Inc., Arab, AL) as previously described [111].
Either 20, or 30 wt % PEGda was mixed with phosphate buffered saline (PBS) and 0.5 wt% of
the photoinitiator (PI) Irgacure 2959 (I-2959, Ciba Speciality Chemicals Corp., Tarrytown, NY).
One gram (g) and one milliliter (mL) are used interchangeably. A buffer was chosen because
resulting experiments would include the use of cells. These cells require an environment similar
to that of the body and PBS resembles better physiological conditions than pure water.
Moreover, the PI used here has been proven to be cytocompatible [112]. According to the
weight percent (wt%,) equation, Table 3.1 shows the proportions that took place depending on
the PEGda concentration desired.

wt % =

x
.x 100%
x+y+z

Where:
x = grams of PEGda,
y = grams of PI and
z = milliliters of solvent (PBS)
x + y + z = 100%
For these specific solutions:
x + y + z = 2.0mL
z = 0.5 % fixed PI conc.

Knowing that the concentration of photoinitiator will not change, the volume of solution
wanted (mL) and the component percentage desired (g) can be calculated by solving for x, y or z,
as required.
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Solving for x to calculate the grams of PEGda needed for a 20 wt% PEGda solution (sol´n):
20 % =

x
2.0g

.x 100%

x = (20 %) (2.0g)
100 %
x = 0.4 g PEGda
Solving for y to calculate the grams of PI needed to obtain 0.5 wt% PI of a PEGda sol´n:
0.5% =

y
2.0g

.x 100%

y = (0.5%) (2.0g)
100 %
y = 0.01 g PI
Solving for z to calculate the mL of solvent to obtain 79.5 wt% PBS of a PEGda sol´n:
79.5% =

z
2.0g

x. 100%

z = (79. 5%) (2.0g)
100 %
z = 1.59 mL PBS

Table 3. 1. Amount of reagent required according to its desired concentration

20%PEGda
79.5% PBS
0.5% PI
30%PEGda
69.5% PBS
0.5% PI

PEGda(g)

PBS(mL)

PI(g)

0.4

1.59

0.01

0.6

1.39

0.01

Poly(ethylene glycol) diacrylate was taken out of the freezer and left on the counter at
least one hour to reach room temperature (RT) before being opened. Then, the components were
weighed and then mixed in an amber vial as PEGda is sensitive to light and it is desired to avoid
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any reactivity that is not controlled. For at least two hours the vial was left in a vortex (VortexGenie 2, Scientific Industries, Inc.,) because it is hard to dissolve the photoinitiator even though
the provider´s information claims it to be readily soluble in water and PBS is an aqueous
solution. The vial was anchored to the vortex´s base with insulating tape strips. Care should be
taken as the base of the vortex often detaches and the amber vial can be ejected causing an
accident. The photopolymer solution was taken inside the biosafety cabinet (BSC) (Purifier
Class II, Labconco Corp., Kansas City, MO) to be syringe filtered. The solution passed through
a low protein binding syringe filter (0.22 μm filter, Cole-Parmer, Vernon Hills, IL) and was
transferred to a previously autoclaved amber vial.
Note: A little bit more of solution than the actual needed was always prepared. Some is
lost in the filtering process and in the pipette tips when transferring solution. In addition,
calculations resulting in, for example, 100 % = 2g of solution does not make 2 mL in volume
(even though they are equivalent in weight).

Figure 3. 1. Final steps to prepare a sterile photopolymer solution
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3.1.1.2

PEGda 6 kDa Photopolymer Solutions
This solution was prepared from 6 kDa PEGda as a 10% weight of solute in volume of

solvent (w/v) to compare the release properties of PEG between different molecular weights and
concentrations. Following the directions of our PEGda 6 kDa provider and colleague at the
University of Utah, Dr. Brenda K. Mann, 6 kDa PEGda hydrogels were crosslinked in a different
manner than PEGda 3.4 kDa. The polymer solution was prepared by mixing 1.0 mL PBS and
0.1 g PEGda 6 kDa. Next, the photoinitiator 2,2-dimethyl-2-phenyl-acetophenone (DMPA) was
dissolved in 1-vinyl-2-pyrrolidinone (NVP) at 300 mg DMPA per mL NVP. Then, 10 µL of the
dissolved PI were added per mL of photopolymer solution and mixed by pipetting up and down.
PI solution (DMPA in NVP) was always added to the PEG solution with or without NGF always
at last, since this prepolymer solution is good to use only few minutes after combining its
reagents, more specifically after adding the PI. After a few minutes of adding DMPA in NVP to
the PEGda solution, the vial´s contents exhibit a phase separation that makes an uneven and not
homogeneous solution.
One more different step between the 3.4 kDa and the 6 kDa PEGda solutions is that this
last one was not filter sterilized. The reason to sterilize is the possible use of the solution or
resulting hydrogels with cells, but DMPA in NVP is cytotoxic and thus, there was no concern
with sterility if the photoinitiator itself will kill cells. Even then, every step was carefully done
in a clean environment where surfaces were wiped with 70% ethanol
Notice that there were discrepancies on how to express the concentration of the solutions
and. The agreed terminology is as stated in this thesis: wt% for the previously explained 3.4 kDa
PEGda preparation and % (w/v) for the 6 kDa PEG solution preparation procedure. Table 3.2
shows the concentration in terms of grams of PEGda per milliliter of solvent (PBS).
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Table 3. 2. Column on the left describes the concentration of solution either in
(w/v) or wt%. Column on the right states the grams of PEGda required per
mL of PBS to achieve the desired concentration provided by the left column

3.1.1.3

Concentration

PEGda/PBS

10% (w/v) PEGda 6 kDa

0.1 g/mL

20 wt% PEGda 3.4 kDa

0.25 g/mL

30 wt% PEGda 3.4 kDa

0.43 g/mL

PEGda stock solutions
These were solutions of 3.4 and 6 kDa PEGda that were prepared in siliconized sterile

2mL microcentrifuge tubes (Low Retention, FisherScientific) to take a small part of them to
react PEGda in excess with NGF and bond them chemically. Their preparation took place while
an NGF aliquot was equilibrating to RT. The solvent was PBS pH =7.6. The solution was
syringe filtered before combining it with the neurotrophin.
3.1.1.4

Nerve Growth Factor
Nerve growth factor (mNGF, 2.5S, Promega Corp., Madison, WI) was reconstituted in

plain RPMI-1640 with 100 g of bovine serum albumin (BSA) per mL of medium as a protein
stabilizer. In a 15 mL polypropylene (PP) centrifuge tube (CT) 10 mL of plain RPMI-1640 were
supplemented with 1 mg of BSA. This PP tube was used to prevent absorption of protein by its
container [40].

The solution was taken inside the BSC to be syringe filtered.

With a

micropipette and sterile pipette tips (Eppendorf Inc., AG, Hamburg, Germany), only 100 µL of
the sterilized solution were taken and added to the NGF vial to a final concentration of 1 g/L
of NGF in medium (original NGF vial contained 100 µg of the protein). The solution was split
into siliconized microcentrifuge tubes to minimize NGF adhesion to the walls of its container
and leftovers were kept in the original container. The purpose of this was to take NGF as needed
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from aliquots and avoid multiple freezing-thawing a single NGF solution. The reason to aliquot
is that NGF is susceptible to denature (change in protein structure and thus, lose biological
activity) due to constant temperature changes. The splits were in duplicates of 20 and 13 µL
since they were further used to add them to 3.4 kDa PEGda or 6 kDa PEGda solutions,
respectively, for encapsulation or conjugation. 20 and 13 µL are not random numbers. It was
the amount of NGF calculated to entrap or link to PEGda to ultimately produce a photopolymer
solution capable of making disks of 500 ng of NGF to release per hydrogel. Aliquots were
stored at -20 oC in a freezer (Thermo Electron Corp. Asheville, NC) until used. Figure 3.2
illustrates the split.

NGF
[1µg/µL]
100µL

NGF
[1µg/µL]
20µL

NGF
[1µg/µL]
20µL

NGF
[1µg/µL]
13µL

NGF
[1µg/µL]
13µL

To
encap.
3.4kDa
PEG 20%

To
conjug.
3.4kDa
PEG 20%

To
encap.
6kDa
PEG 20%

To
conjug.
6kDa
PEG 20%

Figure 3. 2. NGF aliquots and their further use. Rectangles resemble 2 mL microcentrifuge tubes
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Calculations for 3.4 kDa PEG hydrogels indicate that 1mL of photocrosslinkable solution
can make up to 80 disks (Appendix 4).

Since each disk was intended to contain 500ng,

multiplying the number of disks desired times the amount of NGF nanograms (ng) per disk will
give the amount of protein required per mL of solution:
(80)(500ng)= 40,000 ng NGF per mL of prepolymer solution.
According to that, previous NGF aliquots contained the exact amount of protein that would be
used. This makes more sense and it is explained more in detail in the following section and. The
reason to do it like this was to avoid losing NGF while transferring it. Rather than putting in
NGF to PEGda, solutions were prepared by adding the reagents into the NGF aliquot vial.
3.1.1.5

Conjugating PEG-NGF
Taking advantage of the PEG´s characteristic ability to link molecules, NGF was

PEGylated to 3.4 and 6 kDa PEGda end groups. A Michael-type addition reaction took place.
This is, under basic conditions, hydroxyls in solution remove hydrogen from the carboxyl groups
located in the amino acids of the NGF protein, giving rise to a nucleophile. This moiety reacts
with the carbonyl located at the end groups of PEGda attacking the double bond. As a result, a
covalent bond is formed between PEG and NGF and the reaction is reversible as this bond is
hydrolysable. The more basic the solution, the more hydroxyl groups present and the faster the
reaction. However, it has been reported that NGF denatures under basic conditions [113]. Even
though the reaction could have been accelerated, it took place for two hours close to a neutral
environment at pH=7.6.
An NGF aliquot was thawed while a PEG stock solution was being prepared. An amount
of the PEGda stock solution was taken to the NGF aliquot vial in a 1:5 ratio (NGF:PEG). The
purpose of adding 5 times more PEGda than NGF is to increase the possibility that NGF binds to
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only one side end group (ACRL-PEG-NGF and not NGF-PEG-NGF). This leaves acrylate
groups free to later crosslink to an acrylate of another PEGda molecule. The volume was
adjusted to 100 µL with PBS and syringe filtered inside the BSC. Figure 3.3 illustrates for the
conjugation conditions.

Add PEGda from stock

Michael- type
addition reaction
Time: 2hr
ph = 7.6

NGF:PEG
1:5 ratio

NGF aliquot
2mL microcentrifuge tube

~100 µL PBS

Figure 3. 3. Michael-type addition reaction conditions

Even though the exact percentage yield (% yield) is unknown, the initial amount of
protein is still present either conjugated to PEG or unreacted (not linked to PEG, but remaining
in solution). The only difference between the conjugation reaction between NGF and PEGda of
3.4kDa or 6kDa PEG, was that for the lower mw, the resulting ACRL-PEG3.4kDa-NGF was
lyophilized and thus, turned into a powder, whereas the ACRL-PEG6kDa-NGF 100 µL were
directly stored under -20 oC until used.
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3.1.1.6

Photopolymer Solutions Containing NGF
From the early prepared solution (20 wt% PEGda 3.4 kDa) a part was taken as calculated

to add to the NGF aliquot vial, inside the BSC. As stated before, with the objective of not losing
any NGF and having the same amount of protein from encapsulated or conjugated. The final
solutions contained NGF (linked to PEG or entrapped) to produce hydrogel disks containing 500
ng to release per disk. The NGF aliquot vials containing then the photopolymer solution were
wrapped with aluminum foil and used immediately. Figure 3.4 shows how the crosslinkable
solutions were prepared for 20 wt% PEGda 3.4 kDa with NGF either conjugated or encapsulated.

Addition of 20wt%
PEGda 3.4kDa
solution

Addition of 20wt%
PEGda 3.4kDa
solution

Lyophilized powder
ACRL-PEG3.4kDa-NGF

NGF aliquot

Figure 3. 4. Left: Photopolymer solution containing NGF chemically bonded to
PEG3.4kDa. Right: Photopolymer solution containing the protein free in solution

The following image depicts the way in which 10% (w/v) PEGda 6 kDa solutions were
obtained with the protein encapsulated or conjugated.

Note that also for these solutions

everything was calculated from the beginning as to maintain the same amount of NGF from start
until the time of curing. For example, the conjugation reaction took place in a volume of 100µL.
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It contained 40,000 ng NGF as the potential amount to be conjugated. Then, 0.1 g PEGda 6 kDa
were added, 900 µL of PBS buffer and 10 µL of DMPA in NVP to the 100 µLPEG-NGF
solution leading to a 10% (w/v) PEGda 6 kDa solution. The amount of PEG coming from the
conjugation reaction was not taken into consideration within the 10% (w/v) PEGda concentration
of solution. The previously described is shown in Figure 3.5 left. When preparing the solution
of PEG 6 kDa with the protein encapsulated, a similar approach was followed. Again, an NGF
aliquot was thawed and the other components were added. 980 µL PBS were added and other 20
µL came from the NGF solution aliquot. It is important to mention that solutions were mixed by
pipetting up and down. A representative sketch of the components´ combination is found in
Figure 3.5 right.

Addition of PEGda
6kDa solution

Addition of PEGda
6kDa solution

ACRL-PEG 6kDa-NGF
in 100µL PBS

NGF aliquot

Figure 3. 5. Addition of components to achieve a 10% (w/v) PEGda 6kDa
containing NGF covalently linked (left) and free NGF in solution (right)
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3.1.1.7

Stereolithography
The unit used to build the hydrogels presented here is a 3D Systems® stereolithography

(SL) machine model 250/50. More detailed information about its function is given in Ch.1 in the
stereolithography section. The SL machine´s inside and outside surroundings were wiped with
70% ethanol to get rid of dust as much as possible. It was turned on 30 min before starting to
build allowing the SL machine laser to warm up. Previously, with the aid of SolidWorks™ and
3DLightyear™ (3D Systems®, Valencia, CA) softwares, an .stl file was created which contained
the drawing of six cylinders. The drawing dimensions were smaller than the actual hydrogel
desired size taking into account the dimensional swelling factor (DSF) [111]. By the DSF, we
know that 20% PEG 3.4 kDa hydrogels increase their volume after constructed when left under
an aqueous environment (specifically, PBS). The calculations were prepared so that each feature
had 500 ng NGF to release whether swollen or shrunk. The .stl file previously uploaded to the
system of the SL machine was opened to build six disks (one layer of the cylinders) per batch at
the same time (An illustration for this can be found in Ch. 5, Figure 5.1). The elevator was fixed
at the original position where the beam diameter is ~250µm [111] and stood static while
constructing, since only one layer was built per batch. The laser power was measured before
building with a power meter and compared its reading to the one given by the system. If there
was variance, the apparatus parameters were edited as to show the reading that was given by the
power meter. In addition, the laser position was also adjusted accordingly. The parameters to
build were a critical exposure (EC) of 12.00 and a penetration depth (DP) of 2.82 based on [114].
The laser speed (LS) varied from 0.97 to 1.17 and the laser power (LP) oscillated from 21 mW to
23 mW.
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The SL machine´s modifications for manufacture were those previously defined
[111,112], where a small vat was used instead of a big container as can be observed in Figure
3.6.

a)

b)

Note the absence of
a container

Figure 3. 6. Modifications to the SL system. a) SL model without its original
container, b) base adapted to elevator platform attached with clay

To overcome some drawbacks, the mini-vat was also modified. One of the difficulties
was that due to the fact that finished features are relatively small and tend to highly attach to
bottom of the container where they are being constructed. It is too hard to remove them from the
surface. Also, NGF is expensive and its availability is limited. For this reason, it was important
to reduce the amount of solution required to build per layer. To overcome these problems two
modifications were made:
1. The inner diameter of the container was reduced shown in Figure 3.7.
2. A transparency was pasted to the bottom of the container.
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In this way, less solution was required to cure one layer and the hydrogel parts were
removed easier and came out of higher quality (complete, not broken), as they were disturbed
less with the spatula at the time of detaching them from the bottom of the mini-vat. To paste the
transparency, a piece of transparency was cut of the size of the modified inner diameter. Then, a
resin drop was distributed with the aid of an applicator and the transparency was placed on top.
With a clean applicator the transparency was pressed to the bottom of the vat until no air was
seen underneath. Next, a UV spot light (Green Spot™, UV Source, Inc.) was applied to cure the
resin in between the surface of the vat and the transparency, which ultimately glued them. An
image of the vat modifications is given in Figure 3.7. The yellowish color is because the picture
was taken after crosslinking PEG 6 kDa where this vat was also used. The wavelength was
longer and intensity of the laser was higher, overcuring the mini-vat and changing its color.

Figure 3. 7. Vat on the right is the new modified. Note the reduction of the
inner diameter to reduce the amount of solution required to crosslink one layer .
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The inner diameter of the new smaller container was measured with a caliper (Fig. 3.8) to
be able to accurately calculate the amount of solution required to crosslink one layer of solution
in this specific vat based on its dimensions.

Figure 3. 8. Inner diameter measurement of the
new container of smaller inner diameter (20.4 mm).

3.1.1.7.1

Building in SLA

Six disks (number of samples (n) = 6) were built at the same time (per batch). After
wiping with ethanol inside, outside and tools to be used, the base of the vat was leveled. A
leveler was placed on top of the container over its base and the clay helped to set in place the
base of the vat. The 24-well plate previously filled with 2mL of RPMI-640 per well was taken
close to the building machine as well as a clean spatula. Control disks were built first. Controls
consisted of the photopolymer solution only that without NGF. They were manufactured first to
avoid contaminating them. 340µL were dispensed with a micropipette into the vat (Fig.3.9).
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There was a need to evenly distribute the solution at the time of dispensing it with the aid
of the pipette. This was done by touching (scanning) the container surface with the pipette tip as
solution is coming out. The solution has preference for the walls of the container and an empty
space at the center can be the result with the solution at the edges (meniscus) if not distributed.

Figure 3. 9. Photopolymer solution being dispensed
from a micripipette into the modified container.

Then, the laser was commanded to pass once over the solution to crosslink one layer of the
cylinders´ file (Fig.3.10), leading to the creation of six hydrogel disks.

Elevator
platform

Container
Base

Clay

Figure 3. 10. Laser beam (blue spot) passing over the photosensitive solution.
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First batches served to center the position of the vat and to make sure the laser was not
hitting the walls of the container. Immediately after the disks were built, the vat was taken out of
the chamber.

The unreacted solution was retrieved with the pipette and sent back to its

container. Taking reagent from a container and taking the unused back to the bottle is usually
unaccepted. However, unreacted material in this case can be recycled at the moment (not stored
to use another day). The disks were rinsed with ultrapure water three times to get rid the most of
unreacted material at the surface of the hydrogels. The third time of rinsing, water was not
discarded to avoid ejecting the disks at the time of removing them with the spatula. Hydrogels
were individually transferred to wells of the 24-well plate (Fig. 3.11).

Figure 3. 11. Hydrogels placed individually into wells of a 24-well plate in
RPMI-1640. Note the size of the gels versus the volume of solution in
which tNGF is being released.
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Just after constructing the control disks, photopolymer solution containing NGF free in
solution was prepared. An amount from the leftover solution with which the controls were built
was combined with NGF as early stated (Sec. 3.1.1.6, Fig. 3.4 right) just before manufacturing.
PEG hydrogels containing the protein entrapped were created first followed by the ones
containing chemically bonded NGF. Next, photocrosslinkable solution was mixed with ACRLPEG-NGF (Fig. 3.4 left) and the same procedure as explained for controls took place to build
disks containing the protein covalently linked.
The same procedure was repeated with a 30 wt% PEGda 3.4 kDa solution. Controls were
created first followed by hydrogels containing NGF. The only difference is that from this
concentration only hydrogels with the neurotrophin trapped within the polymeric mesh were
created and not conjugated. This was to compare the release rate between solutions of the same
molecular weight but different concentration (30 wt% PEG 3.4 kDa vs. 20 wt% PEG 3.4 kDa).
When all disks were fabricated, the 24-well plate containing them was taken back to the
inside of the incubator at 5% CO2, 37 oC and saturated moisture. Even though temperature
readings were given digitally by the incubator, a thermometer was placed inside to confirm
temperature conditions.
3.1.1.8

PEG 6 kDa hydrogels manufacture
Due to the fact that we have not been able to gelate 10% PEGda 6 kDa solution under the

stereolithography system, a different methodology was followed to create these hydrogels. The
setup consisted on a OmniCure® spot UV lamp Series 2000 of long wavelength (λ = 365nm).
Since the lamp is flexible, it was set at a working distance of 15 cm (height above the
photosensitive solution). A white sheet was placed at the bottom surface where the light would
hit. On top of the sheet, the same vat utilized in the SL machine was placed. The white paper
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served as an indicator to center the vat. In addition, it served to indicate the position of the vat
and put it on the same spot every time. 400 L of crosslinking solution were taken and
dispensed evenly into the vat. The light was turned on with an automated fixed exposure time of
5 min. and cured a whole layer of solution. Figure 3.12 provides the setup utilized.

b)

a)

c)

Figure 3. 12. Sport light UV radiation setup. a) Side view, b)front view, c) close -up top view.
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To use as a mold to retrieve disks from the hydrogel layer, an Eppendorf™ pipette tip of
2-200µL was sanded from the outer diameter of its bigger opening (where the pipette fits) to
have a circular knife-edge. Its inner diameter was measured with a caliper to confirm it had a
size of 5mm (Fig. 3.13).

Figure 3. 13. Pipette tip mold to shape
circular hydrogels. a) Unsanded pipette
tip, b) sanded pipette tip from its outer
diameter, c) measuring the inner
diameter.

a)

c)

b)
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Similar to the process of building in SL, control disks were created first followed by disks
containing the neurotrophin embedded and then having it chemically attached. Since a single
layer was cured and not individual disks, the mandrel-like pipette tip was used to take them out
of the mold. Taking a look at the layer cured (with or without the disks) it is noticeable that the
PEGda 6 kDa solution also had affinity for the walls of the container. The area at the center is
thin in comparison to the thicker perimeter (Fig.3.14b and c).

a)

b)

c)

Figure 3. 14. a) Hydrogel extrusion method, b) cured layer without
the disks, thin at the center, c) cured layer thick from the perimeter.

When taking away the excess material, disks were left attached to the bottom of the vat.
Disks were rinsed three times and the procedure followed was similar to that described before
when treating with PEG 3.4 kDa hydrogels. In the case of PEG 6 kDa disks, only 5 samples
were created instead of 6 as with the SL process.
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3.1.1.9

Lyophilized-Sterilized Hydrogels
In order to come closer to the real necessities and demands, a group of disks containing

the protein entrapped went through the sterilization process to prove if they could withstand
these conditions. The reason for this is that the market will require the sterilization of conduits
for implantation and lyophilization for storage. Hydrogel disks of a 20 wt% PEGda 3.4 kDa
solution were built. Two batches were built and rinsed: one for the control and the other were
hydrogels with the protein embedded. Immediately after constructed, they were transferred with
a spatula to 2 mL siliconized microcentrifuge tubes. The tubes had holes in the lid that were
made with a 15 gauge needle. Tubes containing the disks were submerged right away into liquid
nitrogen (N2(l)) (Figure 3.15). Then, the microcentrifuge tubes were transferred to a FreeZone®
lyophilizer (Labconco Corp., Kansas City, MO) to remove moisture from gels. After the freezedrying process, disks were shipped to the University of Utah to receive hydrogen peroxide
(H2O2) gas for sterilization and were received back to proceed with the releasing experiment.
Once lyophilized and sterilized, hydrogels were taken as stated above individually into 2mL of
RPMI-1640 to release their contents.

Figure 3. 15. Left: Top view of microcentrifuge tubes inside liquid nitrogen. Tubes
contain disk shaped hydrogels. Right: Hydorel disks taken out of the liquid
nitrogen container. A red pen is included in the scenario to provide a sense of scale.
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3.1.1.10

Time Points

Control disks were left in solution from start to end of the experiments. Solutions
holding the released protein from disks that diffused the physically trapped NGF were retrieved
after 2, 4, 8, 12, 24, 48 hours and 1 week. Regarding hydrogels with the covalently linked NGF,
solutions were recovered after 4, 8, 12, 24, 48 hours, 5 days and each subsequent 5 days until
reaching 1 month. Each well was replenished with fresh medium every time after solution was
taken out and the process was done inside the biosafety cabinet. Samples were stored in 2 mL
siliconized microcentrifuge tubes at -20C until analyzed by enzyme-linked immunosorbent assay
(ELISA) for NGF quantification or until used to prove for bioactivity by exposing
pheochromocytoma (PC-12) cells to this medium.

a)

b)

c)
Figure 3. 16. a) Retrieving supernatant, b)transferring to 2mL siliconized
microcentrifuge tubes, c) Replenishing hydrogels in wells with RPMI-1640.
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When solutions were retrieved, care was taken to avoid scratching the hydrogels with the
pipette tip. The surface of the of the 24-well plate was not touched and different pipette tips
were used to avoid cross contamination.

Moreover, before retrieving the supernatant, the

solution was pipetted up and down at least three times to assure a homogeneous sample solution.
It was very important to keep track of the solutions. To know exactly which supernatant
was from which disk, vials were labeled individually on top of their lids before taking them
inside the freezer (Fig. 3.17). A marker was used to this end which ink withstands a wide range
of temperatures and is hardly removed by common solvents (ethanol or acetone, for example).
In addition, the case container was also labeled on the outside (both container and its lid) to
identify it inside the freezer rapidly and easily.

a)

c)

b)

Figure 3. 17. a) Individually labeled tubes still in rack, b) samples moved
to a case after labeling and c) labeled case placed inside a -20oC freezer.
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Each time a time point solution was retrieved it was split into two tubes. From the same
well, one sample went for ELISA analysis and another one for the PC-12 cell bioassay. With
this, the same solution was used for ELISA and cell exposure. Figure 3.18 shows the split.

To quantify
by ELISA

To analyze
bioactivity
by PC-12

Figure 3. 18. Split of retrieved supernatant.
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3.1.1.11

ELISA

A sandwich enzyme-linked immunosorbent assay (ELISA, NGF Emax®, Promega Corp.,
Madison, WI) was performed on the samples to quantify the amount of protein released
following the manufacturer instructions (Appendix 1). According to the instructions, buffers
were prepared fresh the same day they were being used except for the washing buffer that was
prepared once at the beginning of the analysis. To adjust the pH of solutions, the pH meter was
calibrated in three points (4,7 and 10) with a resulting slope of 98.6. 96-wells ELISA nunc™
plates (Rochester, NY) were used for the assay. For every plate, a standard curve was prepared
and only the linear portion of the curve was used to calculate the amount of NGF in the samples.
Samples were diluted with the same buffer that was used for the standard dilutions. To know the
dilution factor required for the samples, a plate was read with one sample of each time point and
controls. Controls consisted of the supernatants of hydrogels without protein. Blanks consisted
of the buffer that was used to perform the dilutions. Every time the plate was left settled it was
covered with Parafilm®. Whenever the protocol indicated the need of shaking the plate, an
orbital shaker was used and motion was set at 500rpm. At the end, the plate was read in a
VersaMax™ microplate reader at λ = 450nm within the first 30 min after adding 1.0 N HCl for
stopping the reaction.
Every sample´s absorbance has to fit in between absorbance values of the linear portion
of the standard curve. After reading the plate, one can get an idea of how concentrated the
solutions are by looking at the plate´s color. For example, Fig.3.19 shows a plate with samples
before stopping the reaction. The samples are still blue because HCl has not been added yet.
Once HCl is added, color turns yellow in different intensities. For the plate shown, the last two
columns contain the standard curve samples in serial dilutions from top to bottom.
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The most concentrated samples of the standard curve are in the first row of the last two
columns and the intense blue can be observed. From there down, the blue intensity decreases
directly proportional to the concentration of NGF in the standard curve. All other wells contain
different ranges of blue meaning different concentrations of the protein.

Figure 3. 19. ELISA plate with samples and standard curve before the addition of 1.0 N
HCl. Note how the samples concentration can be compared with those of the standard
curve according to the color intensity. Standard curve is located at the two last columns
in serial dilutions from top to bottom.

3.1.1.11.1

Remarks About ELISA

-

Buffers were prepared as stated in the protocol for accurate results.

-

When adjusting the pH of buffers, NaOH or HCl were added drop by drop.
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-

When throwing contents in the sink, the plate was turned upside down fast to avoid cross
contamination. It can be the case that the contents of a well invade an incorrect well if
this is done slowly.

-

Also, when flicking the plate over the counter (paper towels in between counter and
plate) it was done fast for the same reason as stated above.

-

ELISA reactions can be slowed down or sped up by decreasing or increasing the
temperature, respectively.

This is accomplished by placing the plate inside the

refrigerator (4 oC) or inside the incubator (37 oC). Before adding the samples, coating
and blocking processes can be made faster or slower. Advantage of this was taken when
diluting the samples. While dilutions were taking place, the plate was taken inside the
refrigerator if samples were not ready to follow the protocol. However, after addition of
the sample times have to be respected and protocol´s procedure followed. For example,
if the 2nd antibody is left incubating more than the specified time, it can lead to too much
background and thus, a noisy signal as a result [115].
-

When choosing the multichannel pipette between an 8 or 12 channels, the 8 multichannels pipette was preferred since it is easier to handle.

-

The plate reading has to take place no more than 30 min after stopping the reaction.

71

3.1.1.11.2

Quantified NGF Released

To change from absorbance values to concentration of protein in total NGF ng released data
was organized in graphs. A linear equation given by the linear portion of the standard curve was
used to perform the calculations (Fig. 3.20).

a)

b)

Figure 3. 20. a) Example of standard (stdr) curve from one of the read plates and
b) linear portion of stdr curve showing the r-value and linear equation of the graph.
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From the previous equation (Fig. 3.20b) the concentration can be calculated by solving for x.
y = 0.0151x + 0.0836
x = (y-0.0836)/0.0151
Where:
y = absorbance and
x = concentration of NGF in pg/mL
The resulting concentration (pg/mL) was multiplied by the dilution factor or the sample. It was
then divided by a thousand to convert from pg to ng. Last, it was multiplied by 2 mL since it
was the volume of the supernatant. Controls were not subtracted since they gave negative
absorbance and concentration values. This gave finally the total amount of NGF ng present in 2
mL of medium. Table 3.3 illustrates the steps to calculate total NGF per sample.

Table 3. 3. Calculations to know the total amount
of NGF released per sample in a 2mL volume.

Sample Abs

NGF pg/mL
(abs-0.0836)/0.0151)

0.525
0.543
0.464

29.23
30.42
25.19

x dil factor

NGF ng/mL

(NGF pg/mL)

(/1000)

Total ng of NGF
(x 2mL)

5261.7
5476.3
4534.6

5.26
5.48
4.53

10.52
10.95
9.1

However, results were reported as cumulative values. To convert to cumulative values,
each hydrogel release values were tracked. The first time point value (ie. at 2 hrs) was reported
as it is, total ng of NGF (released after 2 hrs). For the second time point (ie. at 4 hrs), its total ng
NGF release values were added with the total ng of NGF of the previous time point (ie. total ng
NGF after 4 hrs + total NGF released after 2 hrs). An average of the added values was calculated
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and plotted. From this mean, a standard deviation was calculated. The standard error (SE) was
also determined. Table 3.4 exemplifies for data management.

Table 3. 4. Data management to acquire cumulative values. Numbers on top of columns refer to
the amount of time in hours that the hydrogels were releasing NGF. Cum refers to the cumulative
value which is the summation of the quantified amount of protein at that time point plus the
previous time point value. Numbers in bold are the plotted mean. In this example n=5

2

4

cum

8

cum

12

cum

Disk1

51.94

6.76

58.69

8.57

67.26

4.63

71.90

Disk2

36.49

6.33

42.81

10.52

53.34

3.75

57.09

Disk3

38.39

7.19

45.58

10.95

56.53

4.99

61.52

Disk4

45.57

4.52

50.09

9.07

59.15

3.42

62.57

Disk5

50.05

4.63

54.69

11.50

66.19

3.23

69.42

AVERAGE
STDEV

44.49
6.87

50.37
6.48

60.49
6.06

64.50
6.05

STERR

3.07

2.90

2.71

2.70

3.1.1.12

PC-12 Bioassay

Pheochromocytoma cells were originally obtained from American Type Culture
Collection (ATCC). However, before their use in this experiment, PC-12 cells were stored
frozen in dulbecco's modified eagle medium (DMEM) plus 5% dimethyl sulfoxide (DMSO) for
at least four years at -140 oC. PC-12s were thawed in DMEM plus 10% fetal bovine serum
(FBS). Immediately after thawing, cells were seeded on a T-25 culture flask. PC-12 cells were
slowly adapted (Table 3.5) to RPMI-1640 medium because they were previously grown and
frozen under DMEM.
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As cells were growing and total fluid renewals (TFR) were performed the following
solutions were given to the cells (Table 3.5):

Table 3. 5. Solutions given to PC-12s to slowly change their medium from
DMEM to RPMI-1640. Through the different fluid renewals, medium containing
different concentrations of media types were varied until only RPMI-1640 was
provided and no DMEM [116].

TFR
1
2
3
4
5

Day
2
4
6
8
10

DMEM (%)
100
75
50
25
0

RPMI-1640 (%)
0
25
50
75
100

RPMI-1640 was supplemented with 10% heat inactivated horse serum (HoS), 5% fetal
bovine serum (FBS), 1% glutamine-penicillin-streptomycin (GPS), 10 mM HEPES and 1 mM
sodium pyruvate.
Cell culture procedures took place inside the BSC. Cells were passaged with trypsinEDTA to a T-75 flask after reaching ~80% confluency. Still, the old T-25 flask containing
leftover cells was kept as a culture backup. PC-12s were cultured and used at their exponential
growing phase for the NGF bioactivity assay.
One day before using cells for the bioassay PC12s were pre-induced to extend neurites.
RPMI-1640 medium was changed for RPMI-1640 supplemented with 20 ng/mL NGF. After one
day, cells were counted, centrifuged (850 rpm x 5 min) and resuspended in media without NGF.
They were then seeded on wells of a 24 well plate at 5000 cells/well. 24 hours were allowed to
pass to let cells adhere to the surface of the wells. After that, their solution was changed for
those released by the hydrogels. Negative controls were PC-12s with fresh RPMI-1640 and PC75

12s with supernatant of disks without NGF. Positive controls were 10 and 20 ng/mL that
allowed for comparison with the released protein from PEG hydrogels. Analysis of neurite
extension was performed under an inverted microscope (Leica DM IRB, Leica Microsystems,
Germany). Images of cells were taken with a CCD camera (Retiga 2000R Fast 1394, QImaging
Corp., Canada) adapted to the microscope at 20X magnification after 24, 48 and 72 hrs.
3.1.1.13

Hydrogels´ Imaging

Pictures of the hydrogels were taken of their normal size and magnified. For the first
images of hydrogels, a digital camera was employed and pictures of hydrated samples were
acquired. For the magnified images dry samples were sputtered with gold for 30s and seen under
a scanning electron microscope (SEM) (S-4800 UHR FE-SEM, Hitachi, Pleasanton, CA).

Figure 3. 21. Scanning Electron Microscope used to take high magnification images of PEG hydrogels.
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3.1.2

PEG Hydrogels with Bioactive Domains
A 20 wt% PEGda 3.4 kDa was prepared. Four mL of HEPES buffer and 0.0251 g of

Irgacure® (I-2959) were added to an amber bottle containing 1g PEGda 3.4 kDa. The solution
was syringe filtered with a low protein retention 2 µm pore size membrane filter. The solution
was split into 2 parts. One part consisted of 20 wt% PEGda 3.4 kDa solution and the other part
was 1mL of solution to which 20 mg of ACRL-PEG-RGDS were added. ACRL-PEG-RGDS
was previously synthesized by another member of our group who also drew the CAD-files that
were used for this experiment [111]. The files consisted of a positive and negative image of the
same drawing. (Fig. 3.22).

Figure 3. 22. Spatially controlled multiple
material manufacture. a) and b) are the
designs provided created in SolidWorks ®
to ultimately produce c) the final desired
hydrogel sketch. Purple sites resemble the
areas where the laser passes scanning.

b)b
)

a)
a
)

c)
c
)

3.1.2.1

Building in SL
Overall, the same procedure took place as in the previous experiment (Section 3.1.1.7).

However, regions within the hydrogels consisted of different files (Fig.3.22) and different
materials. The working area was cleaned with 70% alcohol. SL parameters were a critical
exposure of 12, penetration depth of 2.75, laser speed of 0.929 to 1.3 and a power oscillating
between 22.35 and 27mW. The vat was accommodated with an air bubble leveler and the base
was then stabilized with clay to be attached to the elevator platform. 360 µL of the PEG solution
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that contained RGDS were pipetted into the container and the laser was commanded to draw the
small squares file (Figure 3.22b) by passing twice over the same surface. The vat was taken out
of the system and the unreacted solution was retrieved and placed back into the photopolymer
vial of PEG+RGDS to reuse later. The mini-container was taken back inside the system to its
base and 220 µL more of the same solution were added and again, the laser scanned twice the
same surface. Now, the small squares were tightly attached to the bottom of the vial. One more
time the leftover solution was pipetted and taken back to its corresponding vial. The small
container was rinsed to get rid of the non-crosslinked material. Added water was disposed by
tilting the container. The vat was then dried with a Kimwipe being careful of not damaging the
small features by touching them. With the squares still in place, the container was taken again to
its base inside the SL chamber. The file to use was now changed to cure around the squares only
(Figure 3.22a). 360 µL of the plain PEG solution were added and the laser was sent once to cure
the file sketch. 220 µL more were added and the laser cured one layer again. The uncured
solution was retrieved and re-stocked. The vat was rinsed with ultrapure water and the finished
part was removed with a spatula. Each disk after being created was transferred to a well of a 24well plate containing PBS without flipping the disk.
3.1.2.2

Bioactive PEG Analysis
Inside the biosafety cabinet a 24-well plate was filled with 1 mL of Dulbecco’s Modified

Eagle Medium (DMEM). Hydrogels that were previously in PBS were individually transferred
to a well of the multi-well plate containing DMEM. Since the hydrogel disk fits loosely inside
the well, a silicone ring was placed on top to secure it to the bottom of the well. The rings were
acquired by cutting a silicone hose about 5 mm thick per slice. The rings were previously
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autoclaved and their outer diameter fit tightly into the inside walls of a 24-well-plate´s well. The
well-plate was left inside the incubator overnight at 37 oC, 5% CO2 and 90% humidity.
3.1.2.2.1

HDFs Culture

Human dermal fibroblasts were originally obtained from Cambrex BioScience
(Walkersville, MD).

For this experiment, they were thawed from the biological sciences

facilities where they were under -140 oC. To start, they were placed into a T-25 flask and
transferred to a T-75 once they reached approximately 80% confluency. They were cultured in
DMEM supplemented with 10% FBS and 5% GPS. Conditions were 37 oC, 5% CO2 and 90%
humidity inside the incubator.
3.1.2.2.2

HDFs Seeding

After 24 hours of having the multi-well plate inside the incubator, it was taken inside the
BSC. One day old medium was retrieved and disposed. Each well was filled with 1 mL of cell
suspension at a concentration of 10,000 cells/mL in DMEM.
Under the inverted microscope, images of the hydrogels were taken at 50 and 100X after
24 and 48 hours. Controls consisted of wells with 1 mL cell suspension without the hydrogels
and without the silicone rings.
3.1.2.3

PEG hydrogels´ Fabrication of Compound Materials
To confirm that the stereolithography machine is capable of constructing single parts of

different materials, PEG hydrogels were built containing specific domains of a fluorescent dye
that showed the place where a different material was present. The same procedure as in Section
3.1.2.1 was used.

The differences were the solutions used and the files´ sketches.

The

crosslinkable PEG solution used was a 20 wt% poly(ethylene glycol) dimethacrylate which mw
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was of 1 kDa (PEGDMA MW 1000, Polysciences, Inc., Warrington, PA). It was dissolved in
HEPES buffer and it contained a final concentration of 0.5% Irgacure 2959. The solution was
split in two. One part was kept original without additives and was used to build the area
surrounding the small squares. The other part consisted of 1mL of the original solution plus
20mg dextran labeled with fluorescein isothiocyanate (FITC-dextran, Sigma-Aldrich, St. Louis,
MO) with an excitation/emission of 490/520nm. PEGdma solution containing the fluorescent
dye was used to construct the small squares. The .stl files used are shown in Figure 3.23.

Figure 3.23. Top images (negative and positive)
that give rise to the bottom design when they
are overlapped. Purple sites resemble the areas
where the laser passes crosslinking the solution.

Fabricated hydrogels were immersed in ultrapure water until observed under the
microscope. Images were taken at 10X magnification with the CCD camnera now adapted to a
Leica MZ16 microscope (Leica Microsystems, Germany).
3.1.3

1

H NMR

A proton nuclear magnetic resonance (1H NMR) was performed to characterize PEGda
3.4 and 6 kDa with the aid of a Bruker 300 MHz spectrometer. The following procedure took
place with guidance from chemists at the UTEP´s chemistry department [117, 118]. Sample
preparation involved the dissolution of polymer in deuterated chloroform (CDCl3). This solvent
was chosen because the company from where PEG was obtained stated that PEG is readily
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soluble in chloroform. Moreover, CDCl3 has been reported in literature to be used with PEG
compounds. Furthermore, chloroform has a chemical shift (δ) at 7.27 that does not interfere with
our expected signals. For example, it is known that δPEG = 3.6ppm. If deuterated water (D2O)
were to be used it would have a chance to interfere with the quality of PEG 1H NMR spectrum
since D2O exhibits a peak at δ = 4.8 ppm. In addition, the solvent used had 1% tetramethylsilane
(TMS or (CH3)4Si). This is a highly hindered molecule of δ = 0, used as an internal standard.
The number of repetitive units (n) of the PEGda chain was calculated from 1H NMR.
Ultimately, the molecular weight of the polymeric compounds was confirmed by this method.
The molecular weight of the polymer equals the molecular weight of the monomer times the
number of times it repeats (n).
mwPEG = (mw UNIT)(n)
The monomer repetitive unit is -CH2CH2O- and its mw = 44g/mol. Therefore, the mw of PEG:
mwPEG = 44n
To calculate n, a ratio between the integrated area under the hydrogen (H) atoms´ signal
corresponding to the repetitive units over the area of the H atoms´ peak at the end groups was
estimated. Each signal has to be divided by the number of hydrogen atoms that lead to their
appearance. The integrated area under each signal was calculated and given by the NMR
spectrometer software.

n=

Area of the repetivite units signal
4

Area of the repetivite units signal

÷ Number of hydrogens that account
fot this end group signal
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Figure 3.24 illustrates the chemical configuration of hydrogen atoms in the PEGda
molecule. Each letter corresponds to a different signal in the 1H NMR spectrum. Blue capital
letter A indicates a single peak that will be present due to the repetition of four equivalent H
atoms in the monomer. Small red letters a, b and c indicate the three types of hydrogen atoms
from the vinyl groups that will make the three signals of the end groups to appear in the
spectrum.
a

A

O
PEG´s
chain

b

H

H
O (CH2CH2On)

C C
Acrylate
goup

c

H

c

H

b

C C
H

O

H

a

Figure 3. 24. Poly(ethylene glycol) diacrylate molecular structure. A,a,b
and c show the different H atoms´ chemical organization in PEGda.

The number of repetitive units (n) was then calculated using the signal of the single
hydrogen attached to the carbonyl atom (red small case letter a) as follows:

n=

A
4

a

÷

2

Values for the integrated areas of A and a are given in the results section on the NMR
spectrum for PEGda 3.4 and 6 kDa, respectively.

Finally, the molecular weight of PEG

(mwPEG) was calculated after solving for n and multiplying the n value times 44. Outcome is
presented in the results section, Chapter 4.
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Chapter 4
4.0

Results
This chapter presents the results of two projects. The first one is about the controlled

release of growth factors from PEG hydrogels. The second one comprises the capabilities of
stereolithography to produce parts comprised of different materials. This second experiment was
done in collaboration with another tissue engineering researcher from our group. Additional
results (images and tables) not presented here, are shown in the Appendix 2 and 3.
4.1

Nerve Growth Factor Release
The release of nerve growth factor (NGF) was examined from different poly(ethylene

glycol) matrices. The solutions from which PEG hydrogels were made of consisted of different
molecular weights (mw): 3.4 and 6 kiloDaltons (kDa) and varying poly(ethylene glycol)
diacrylate (PEGda) concentrations: 20 and 30 wt% for PEG 3.4 kDa and 10% (w/v) for PEG 6
kDa.

The main objective of prolonging the protein´s stance within the hydrogels while

controlling its release was accomplished. Not only the different methods of protein inclusion
affected the growth factor release, but also the properties of the gels influenced the yield of free
NGF in solution. Points in the graphs represent the mean ± standard deviation (SD), and the
number of sample replicates (n) is given for each set of data. Information is presented as the
cumulative release, which is the amount of protein detected at a given time point plus the value
of the previous time point analyzed. In addition, a biological assay was performed to test for
NGF bioactivity.

With the aid of the inverted microscope we were able to observe the

morphological changes of pheocromocytoma (PC-12) cells in response to the NGF present in the
supernatant of the samples, showing the protein’s bioactivity.
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Hence, we were able to

demonstrate that the stereolithography technique is a viable method to create PEG hydrogels
containing releasable bioactive nerve growth factor.
4.1.1

Hydrogels’ Imaging
Swollen hydrogels from PEG 3.4 kDa were confirmed to be of 5 mm in diameter after

measurements with a ruler took place (Fig. 4.1). However, 3.4kDa disks were thicker than the
higher molecular weight 6kDa gels, due to the building process. Constructing the 6kDa disks
took longer, giving time to the photopolymer to settle and move to the sides of the container
where it has preference to be and photopolymer solution had more time to settle. Moreover,
hydrogel disks did not have 1mm in height evenly. This can be noted by looking at the side view
of disks over a glass slide (Fig.4.2.).

Figure 4.1. Top view of swollen hydrogels. Diameter is confirmed to be of 0.5cm as predicted

84

a)

b)
c)

Figure 4.2. Side view of swollen hydrogels over a glass slide. a) Disks on top of a glass slide placed at the
edge to be able to measure their height, b) measure of the gel width and c) close up of the measurement .
Note that one side of the gel is in fact 1mm thick, but that height is not even throughout the whole
hydrogel diameter
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Higher magnified images were taken under the scanning electron microscope (SEM) to
explore the physical conditions of the hydrogels. Pictures of gold sputtered dry samples and non
sputtered samples were taken.

Overall, the hydrogels shown are not deformed and their

dimensions look even from the upper view. No significant differences were seen from gold
coated samples and non gold sputtered.

Figure 4.3. Upper: Gold sputtered shrunk (dry) 10% (w/v) PEG
6kDa disk. Down: Non-coated dry gel made of 30 wt% PEG3.4kDa
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4.1.2

20 wt% PEG 3.4 kDa

The protein release from 20% PEG 3.4 kDa hydrogels was analyzed from three batches of
disks of different conditions: with the protein encapsulated, conjugated and lyophilized-sterilized
gels containing NGF physically entrapped. For all of the samples, a small amount of NGF was
released when the experiments were stopped in comparison to the potential NGF available for
diffusion. When the protein was encapsulated, 44±6.9 ng were present in the retrieved solution
of the first time point. By the 2nd day most of the NGF quantified was out (74±6.4) and a total of
93±9 ng were released by the 7th. This was the highest amount of NGF diffused for this mw
concentration as shown in Figure 4.4.

Figure 4.4. Cumulative NGF release over a seven day period from 20%
PEGda 3.4 kDa hydrogels containing the protein encapsulated (n = 5)

By conjugating the neurotrophin to the polymer, its release decreased both in rate and
amount. The release profile of the encapsulated protein was different from the conjugated
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protein diffusion. The first diffusion time point recorded when NGF was physically trapped was
after two hours, whereas it was 4hrs when chemically bonded NGF diffused out. These time
points were different because expectations were a slower NGF release when it was chemically
linked to PEG and a faster release when NGF was physically incorporated. When conjugated,
only 7±1 ng were released at the first time point (4hrs). It is important to mention that besides
the fact that the initial release was recorded after twice the time of the previous incorporation
method, the amount quantified decreased significantly (7ng recorded at the first time point when
conjugated, vs. 44ng when entrapped). Then, a burst was seen during the first two days and then
the protein kept diffusing at a constant rate up to 20 days. Ten days later NGF release was still
sustained (19.6±0.8 ng NGF total quantified after 30 days) as illustrated in Figure 4.5.

Figure 4.5. Cumulative NGF release over a 30 days period from 20%
PEGda 3.4 kDa hydrogels containing the protein conjugated (n ≥ 5)
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Knowing that the market conditions require a sterile product that can be stored, the
experiment was repeated including the process of lyophilization and sterilization. Less than
10ng (7.11 ±0.7 ng NGf) were diffused after one week from sterile-lyophilized-reswollen disks.
Surprisingly, even though NGF was encapsulated in dried-sterilized gels, less than when having
the neurotrophin conjugated leached out, as it can be seen in Figure 4.6

Figure 4.6. NGF release over a 7 day period from 20% PEGda 3.4
kDa sterile hydrogels containing the protein encapsulated (n = 6)

4.1.3

30 wt% PEG 3.4 kDa
To compare how the concentration of the polymer affects the release rate of the NGF, a

30% concentration of the same molecular weight was used as a matrix with the protein
entrapped. Findings were that the higher the PEG’s concentration, the fewer the amount and rate
of NGF that was diffused. After 2hrs, only 25±4.7ng NGF went out. At the 7th day, only
46±4..3ng were diffused and a trend in the graph suggests that the protein would keep releasing.
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Figure 4.7. Cumulative NGF release over a seven day period from 30%
PEGda 3.4 kDa hydrogels containing the protein encapsulated (n = 5)

The following graph summarizes the NGF release outcome from different methods of
incorporation into PEG 3.4kDa hydrogels of 20 and 30 wt % (Figure 4.8).

Figure 4.8. NGF release from PEG 3.4 kDa hydrogels
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4.1.4

10% (w/v) PEG 6kDa
As it is commonly known, diffusion is affected both by the size of the molecule being

released and the size of the matrix´s mesh. In this study, a higher PEGda mw of 6 kDa was used
to build hydrogels for the same purpose as before with the PEG 3.4 kDa scaffolds. Noticeably
more NGF was present in the withdrawn solutions from 6 kDa disks´ supernatants. According to
the ELISA analysis, close to 300ng of the encapsulated NGF went out of their matrix. After the
second day, a constant and slight amount but sustained release is seen thereafter. In contrast to
the lower PEG mw 3.4 kDa gradual diffusion, the release profiles of NGF from PEG 6 kDa show
an accentuated initial burst and a faster release during the first day (Fig. 4.9 and 4.10).

Figure 4.9. Cumulative NGF release over a ten days period from
10% PEGda 6kDa gels containing the protein encapsulated (n = 4)

When the neurotrophin was chemically bonded to the chains of the 6kDa polymer, less of
it was released after 10 days in comparison to the diffusion of the physically entrapped protein.
On the other hand, a slight increase in the amount of NGF in the supernatant over each time
point is observable, reaching 253±47 ng at the 10th day. In accordance to the predictions,
chemically linked NGF initially diffused less than when it was only entrapped within the gel. An
additional quantification was made at the 15th day. Results reveal that a small amount of NGF
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was still coming out of the hydrogels and it the results are illustrated in Figure 4.10. . Moreover,
Fig. 4.11 sumarizes the NGF release encapsulated in comparisson to conjugated to 6kDa gels.

Figure 4.11. Cumulative NGF release over a seven day period from
10% PEG 6 kDa hydrogels containing the protein conjugated (n = 5)

Figure 4.10. NGF release from 10 % (w/v) PEG 6 kDa hydrogels

4.1.5

NGF Bioactivity
Nerve growth factor was released from hydrogels into 2mL of RPMI-1640 medium. The

amount released from the PEG gels was biologicaly significant (>5ng/mL [30]), except for the
lyophilized-sterilized disks. As PC-12 cells mimic neuron cells by extending neurites when
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induced by chemical cues, they were exposed to the supernatannts retrieved to test for NGF
bioactivity, which promotes neurite growth. While some consider processes longer than one cell
body diameter as neurites [102, 105, 107, 119,120], PC-12s´ extensions in this experiment are
considered neurites when their length exceeds the double of the cell body diameter [9,39].
Besides the supernatants, cells were cultured with NGF 0, 10 and 20ng/mL as negative and
positive controls, respectively. Findings indicate more bioactivity for the NGF released from the
PEG 3.4 kDa disks than the 6 kDa gels, even though the higher mw hydrogels diffused more of
the neurotrophin. Moreover, PEG 3.4 kDa supernatants exhibit similar bioactivity to the positive
controls. Chosen pictures to present are after 48 hrs of exposure because cell density was still
acceptable as to appreciate individual cell morphology. Images are from cells seeded in a 24well plate at 5000 cells/well (Fig. 4.12).

CNTRL (-)

CNTRL (+) 10 ng/mL NGF

CNTRl (+) 20 ng/mL NGF

NGF from 30%PEG disks
after 2hrs

Figure 4.12. Phase contrast images of PC-12 cells exposed to different
NGF concentrations. Magnification is 20X
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4.2

PEG Bioactive Domains Incorporated by SL
Hydrogels containing bioactive domains and inert areas were fabricated by manipulating

the manufacturing process. The inclusion of a fluorescent dye served to illustrate the regions
patterned with a different material than the rest of the substrate. Even though the following
figure is not a fluorescent image, the various materials comprising the substrate are clearly
noticeable (Fig. 4.13).

+

=

Figure 4.13. Overlapping the two computer sketches on the left built in SL with different
materials lead to the manufacture of a single part made out of different components

Preservation of bioactivity by those domains was shown. Human dermal fibroblasts
(HDF) cells seeded on top of PEG hydrogels recognized the sites containing the cell adhesion
signal RGDS and anchored to them. Images taken after 24 and 48 hours after seeding resulted
unpleasant to sight (Fig. 4.14 upper image), even though they clearly represent cell adhesion
distribution throughout the hydrogel. Pictures were too bright and of a shiny red. Therefore,
using the software Nero PhotoSnap from Nero Premium 7 images were edited to improve their
quality as follows. First, they were converted into white and black and some pictures were
inverted (white became black and vice versa). Then, bright and contrast were adjusted. Bright
was removed and contrast was added to each image. Following in Figure 4.14 are shown two
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images, an original file and the same picture modified.

Subsequent images are edited

photographs (4.15a and 4.15c).

Figure 4.14. Original image (up) and the same picture after edited (down)

Morphology of the cells provides information about their behavior. Rounded cells are
known to be detached from the surface, while elongated ones are identified to be anchored.
Seeded HDFs exhibited a preference to attach at the indicated sites containing the oligomer
sequence. Cells were found to be organized within the PEG bio-interactive domains. Bioactive
domains correspond to the different sized squares pattern.
Figure 4.15 presents a PEG hydrogel previously customized with bioactive regions of the
material PEG-RGDS. Black or white spots relatively big are air bubbles that were floating
around in solution. A curved bright or obscure shadow is the silicone ring located at the top of
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the disk-shaped hydrogels. The reason why spots resembling the same thing are sometimes
bright and sometimes obscure is because the image was inverted in colors or not, respectively.

~1213µm

a) Hydrogel sketch file for
mapping the regions to which
b) and c) correspond.

c) Big square pattern supporting
HDFs anchorage

~796µm

b) Medium square pattern supporting
HDFs anchorage

Figure 4.15. Top view of HDFs seeded on top of a PEG disk-shaped multimaterial hydrogel. Squares represent the bioactive PEG regions
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4.3

Proton Nuclear Magnetic Resonance
The integrated areas and chemical shifts for the two molecular weights of poly(ethylene

glycol) diacrylate were given by the software of the 300 MHz NMR instrument. According with
this, the number of repetitive units (n) and thus, molecular weights of the two different polymers
were calculated. A more detailed explanation of how was this done is available in Section 3.3 of
the materials and methods, Chapter 3. In addition to the original files (Fig. 4.16 and 4.18),
amplified images of the bottom line are provided to appreciate better all the peaks and their split
(Fig. 4.17 and 4.19). Spectrum modifications were done using Spin Works 2.5.4.
4.3.1

PEGda 3.4 kDa
1

H NMR (300 MHz, CDCl3) δ = 1.25, 1.65, 3.65, 4.32, 5.85, 6.17, 6.42 (Fig. 4.16).

n = 2A/4a = (2)(812758)/(4)(5.02)
n = 78.085 repetitive monomers
mwPEG = (44g/mol)(n)
mwPEG = (44)(78)g/mol

1g/mol = 1 dalton (Da)

mwPEG = 3,436 g/mol = 3.4kDa
4.3.2

PEGda 6 kDa
1

H NMR (300 MHz, CDCl3) δ = 1.7, 2.05, 3.65, 4.32, 5.85, 6.15, 6.45 (Fig.4.18).

n = 2A/4a = 321.89(2)/(1.1954)(4)
n= 133 repetitive monomers
mwPEG = (44g/mol)(n)
mwPEG = (44)(133)g/mol

1g/mol = 1 dalton (Da)

mwPEG = 5,924 g/mol = 6kDa
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b a c
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Figure 4.16. Original 1H NMR spectrum for PEGda 3.4kDa showing the corresponding signal to specific hydrogen atoms
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Figure 4.17. 1H NMR closer view of PEG 3.4 kDa peaks´ split. Integrated areas are shown in blue below each signal. Chemical shifts are in green
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a

c
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Figure 4.18. Original 1H NMR spectrum for PEGda 6 kDa showing the corresponding signal to specific hydrogen atoms
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Figure 4.19. 1H NMR closer view of PEG 6 kDa peaks´ split. Integrated areas are shown in blue below each signal. Chemical shifts are in green
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Chapter 5
5.1

Discussion
This section compares the present work with other relevant studies. Moreover, it tries to

explain the outcome of the results and its significance.
5.1

NGF Release
Theoretically, each disk contents were intended to release 500ng of nerve growth factor.

However, there was not a total control over the hydrogel disks’ dimensions before building, for
which the inclusion calculations may have varied. Still, a comparison between the protein
encapsulated and conjugated was possible, since hydrogels built by either method contained the
same quantity of the neurotrophin regardless if it was slightly less or slightly more than the
500ng predicted.
The reason why the inclusion of the protein was not as expected was due to the
discrepancies between the ideal conditions and the real building parameters. Ideally, adding
~327l of PEG photocrosslinkable solution to the thick walled SL vat would create features of 1
mm in height after the crosslinking process. Unfortunately, the solution has affinity for the walls
of the container leaving an empty space at the center. The approach was then to add more
volume of solution (340L total). Even then, the parts built were thinner on the side closer to the
center (less solution present there to crosslink) and thicker on the side closer to the vat’s walls
(where solution has a tendency to be) and it is illustrated in Fig. 4.2c. Nevertheless, a batch of
disks was built at the same time equidistant from the center. Since hydrogel features made of
20% PEGda 3.4 kDa increase their size by 25% after swelling, disks were designed to be built by
the laser .25 smaller than the desired 5mm in diameter. This is known as the dimensional
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swelling factor defined as the desired swollen dimensions over the drawing design dimensions,
established by another member of the reaserch group. According to this definition and knowing
that the factor for the mentioned solution is 1.25, the formula was applied (sketch dimension =
desired 5mm swollen/1.25) Calculations included 500 ng NGF per disk of 4mm in diameter to
swell to a final 5mm diameter. As a result, even though they were not the ideally expected disks
dimensions, they were all of identical size each containing the same amount of protein to release.

4 mm

Figure 5.1.
Representation of the
hydrogel disks´ distribution in the SL vat.

Drug release profiles often show a high dose release over the first days of their diffusion
commonly known as “initial burst”. In the case of NGF, special attention has to be given to
reduce it, as high NGF levels can be an obstacle that may impede nerve regeneration [30, 121].

103

Moreover, this effect has to be diminished in order to have enough neurotrophin releasing
throughout the desired time course accompanying the wound healing [30].
To counteract for the low retention of the drug by the material that embeds it, NGF was
chemically linked (PEGylated) to PEG by a Michael-type addition reaction. In this way, NGF
forms now part of the hydrogel material. The PEG-NGF bond can be dissociated by hydrolysis,
leaving then NGF free to move. It was hypothesized that this method of protein inclusion would
decrease its diffusion rate at the same time that it would lower the unwanted burst. Consistent to
our predictions, PEGylating NGF did reduce its release in contrast to only trapping it within
PEG. Unfortunately, ELISA revealed that the total amount of NGF conjugated that came out
from 20% PEG 3.4 kDa gels after 30 days did not reach 20 ng. To our awareness, close to 100
ng was the maximum amount of NGF observed from PEG 3.4 kDa out of 500 ng theoretically
incorporated. However, that took place only after one week and no assumptions can be made on
how much could have been released after a longer time. For example, protein closer to the edges
of the disk diffuse faster than the growth factor at the center. An explanation for this is that once
one NGF diffuses leaves a space that might be taken by an inner protein. Again, this new NGF
might leave a vacancy that might or might not be occupied by another [99]. In other words, at
the beginning, NGF diffuses fast and as time goes through, the protein release rate decreases.
For this reason, 7 days might not have been enough opportunity for NGF to find its way out.
Another possible explanation why a small amount of NGF was detected is that it was maybe lost
when rinsing the hydrogels immediately after manufacture. Also, the neurotrophin might have
been denatured and not detected by ELISA. This assay permits the detection of the protein by its
conformation and if NGF suffered any changes in its folding there is a risk of not being
recognized. This is what could have happened to the protein released from the sterilized gels.
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Hydrogen peroxide gas was used for hydrogels´ sterilization after the freeze-dry process, risking
the structure of NGF. Consistent with this, the amount of NGF detected from the sterilized disks
did not reach 10 ng.
Conjugating the protein to 10% PEG 6 kDa hydrogels did not prevent from losing most
of the protein quantified by day 1. Either physically embedded or chemically linked to PEG 6
kDa , NGF released accounted for more than 250 ng from these matrices, considerably more than
hydrogels made of a lower molecular weight, 3.4 kDa regardless of the polymer concentration.
Two variants might have had an effect over this higher diffusion rate and quantity from
10% PEG 6 kDa gels: the increase in molecular weight of the polymer from 3.4 kDa to 6 kDa
and its lower concentration, 10%. This represents less crosslinkable groups. Longer chains
translate in less crosslinkable end groups and lower polymer concentration stands for a less
number of acrylate end groups. This leads to fewer interconnections and bigger holes within the
polymeric mesh due to big spaces through which small molecules diffuse. As a relatively small
unit of 26 kDa NGF easily leaves its carrier, 10% PEG 6 kDa. In contrast, it was found that this
neurotrophin hardly left meshes made out from 20 or 30 wt% PEG 3.4 kDa. As it is commonly
known, diffusion is affected both by the size of the molecule being released and the size of the
matrix´s network [106].
At the same time, the mesh dimensions are dictated by the hydrogel’s precursor solution.
PEG from a wide range of molecular weights has previously been studied for the controlled
release of drugs [106, 108-110, 122,123]. In comparison to other studies on the effect of PEG
concentration in hydrogels [9], results presented here confirm that varying the PEGda
concentration affect the properties of the hydrogels yielding to different release profiles for NGF.
Findings were that the higher the PEG’s concentration, the lesser the amount and rate of NGF
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that was diffused.

Even though at first the emphasis was on controlling NGF release by

conjugation reactions and thus chemically retaining it, results revealed that this objective could
be accomplished by adjusting the polymer’s concentration and mw. The NGF initial burst
release was directly proportional to the molecular weight or PEGda.
The amount of acrylate groups present in the different PEGda molecules confirms the
hypothetical explanation on the relationship between mesh composition and diffusion rate. From
one molecule of PEGda mw 3.4 kDa, acrylates account for 0.042 parts of it. On the other hand,
PEG mw 6 kDa exhibits that only 0.024 of the molecule composition is from acrylates. This
resembles the fact that there are more reactive groups for crosslinking in the lower PEG
molecular weight. The higher the molecular weight, the less ACRL groups. Regarding the
solutions of varying molecular weights and PEG concentrations, Table 5.1 summarizes the
approximate molar amounts of end groups per solution used, assuming 100% acrylation. Note
that the solution of highest concentration and lowest mw (30% PEGda 3.4 kDa) has the highest
molar concentration of acrylates.

Table 5. 1. Acylate molar concentration in the solutions involved for
hydrogels fabrication that were used to test NGF release

PEG mw

Sol´n

ACRL

(kDa)

%PEG

[M]

10
20
30

0.033
0.147
0.253

6
3.4
3.4

NGF diffusion from PEG hydrogels of 3.4 kDa PEGda precursor solution was constant
and took place smoothly. Other carriers such as microspheres [99] and microtubules [100] have
shown to effectively reatin drugs, proteins and release them at a desirable rate. However, they
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might jeopardize the conduit stucture by making it vulnerable to defects. Furthermore, the use of
organic solvents for drug vehicles formation might trigger proteins by denaturing them, thus,
compromising their bioacitivity [106]. A positive issue in this study is the fact that NGF was
directly incorporated into the nerve conduit hydogel.

Even though the amount of protein

released was less than the expected, our objective was met. We were able to decrease the rate
and amount of protein diffusion while retaining it longer within its matrix by linking the nerve
growth factor to the polymer with covalent bonds. Moreover, we have shown that the NGF
diffusion behavior can be controlled by changing the molecular weight and concentration of
PEGda.
5.2

NGF Bioactivity
Many studies have been done to identify the range of NGF concentration in the body

[124-127]. Concentration is an important aspect to take into consideration when proposing
methods for this cue release. Even though NGF is the most widely known of the neurotrophins
[69], little and non reliable information is found regarding NGF levels in healthy people or
individuals with a pathology.

Literature supports this conclusion by presenting huge

discrepancies in the quantity of NGF found in serum [128] or plasma [129] among different
research studies or within the same study [69]. Based on this, it is hard to predict the NGF
amount to provide in a nerve scaffold for further release. Yet, a research group suggests that
>5ng/mL is presumably the NGF amount provided by the body [30].

Our release profile

demonstrates, overall, higher NGF levels released. Even though higher amounts of the protein
were washed out from 10% PEG 6 kDa hydrogels than from 20 or 30 wt% PEG 3.4 kDa gels,
bioactivity was conserved only by NGF diffused from PEG 3.4 kDa disks. It is assumed that
this might be due primarily to the process of photocrosslinking. NGF could be denatured when
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exposed to UV light and bioactivity might be affected by the time NGF spent in solution.
Different systems were used to gelate PEGda 3.4 kDa and PEGda 6 kDa. The creation of the 6
kDa disks involved a different photoinitiator and exposure to UV radiation (λ=365nm) for a
longer time (5 min) and a closer working distance than PEG 3.4 kDa curing conditions. Even
though producing sterile PEG hydrogels is still a limitation, it was shown that the
stereolithography technique is a viable method to create PEG hydrogels containing bioactive
nerve growth factor.
5.3

PEGda Characterizarion

Characterization of materials is a very important step in every study. Knowing the materials can
give an explanation of the outcome results where they were employed. For the molecular
examination of PEGda, proton NMR (1H NMR) spectroscopy was used.

1

H NMR has ben

widely used to incursion into the structural parameters of hydrogels [130, 131]. Specifically,
poly(ethylene glycol) has been tested by 1H NMR to confirm the modifications done to the
polymer such as inclusion of functional groups [132].

NMR characterization is usually

accompained by another method of analysis such as gel permeation chromatography [133, 134].
Although, for the purpose of relating more in depth with the differences between the low and
high mw of PEG proton NMR gave us enough information. However, more advantage can be
taken from this instrument since it involves a simple technique and it is usually not time
consuming if the researcher is well related with the spectrometer.
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Chapter 6
6.0

Conclusion
It was shown that the stereolithography technique allows for multiple material parts

fabrication. Localized regions of PEG hydrogels patterned with the material containing a cell
adhesion signal or not having it were evidenced. Regarding protein release from PEG gels, a
decreased growth factor diffusion rate was achieved when protein was covalently bonded to
poly(ethylene glycol). It was also demonstrated that a higher release is obtained when NFG is
only embedded into its matrix. The protein release rate was shown to be directly proportional to
the molecular weight of the polymer and indirectly proportional to the concentration of PEG.
Poly(ethylene glycol) diacrylate is a suitable material to build hydrogel scaffolds for
peripheral nerve regeneration. The inclusion of biologically active moieties was possible with
the aid of a rapid prototyping technique, stereolithography. Moreover, the sustained release of
nerve growth factor was achieved over a period of 30 days from poly(ethylene glycol) hydrogels
of 3.4 kDa molecular weight.
6.1

Future Work
The next step to improve the present work and give continuity would be to explore

methods to obtain sterile hydrogels with retained bioactivity. In addition, advantage of the layer
by layer manufacture process of SL can be taken by building scaffolds with nerve growth factor
(NGF) gradients, since it is known that axons grow in the direction of low to high NGF
concentration [135]. Furthermore, PEG molecular weights and concentrations could be varied
within the same hydrogel to control localized incorporation and release of chemical cues.
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6.2

Recommendations
To improve accuracy, a repetitive pipette is recommended to dispense solutions. This

should be taken into account specially when filling multi-well plates to reduce variance due to
the human error.

The use of a repetitive pipette is also a less time consuming process.

Regarding the conjugation reaction, it is important to find a method to be able to report the %
yield of the reactions done. However, one should take into consideration the amount of sample
needed for testing and the quantity that is available both for analysis and experimentation. In
addition, the same sample that is analyzed is the one that should be used for the investigation.
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Appendix 2

Conjugated NGF Cumulative Release from 20 wt% PEG 3.4 kDa (units are ng if not specified)
Time (days)
0.17
0.33
0.50
1
2
5
10
15
20
30

Disk1
8.184
10.350
12.067
14.694
16.658
18.485
19.684
20.357
20.773
20.873

Disk2
6.223
8.618
10.170
12.620
14.760
16.747
17.915
18.483
18.882
19.000

Disk3
5.809
8.270
9.770
12.146
14.215
16.688
18.313
19.028
19.472
19.607

Disk4
6.576
9.226
10.632
12.875
14.532
16.100
17.552
18.118
18.645
18.763

Disk5
7.764
10.073
11.502
13.893
15.657
17.587
19.222
19.769
20.095
20.206

Disk6
7.478
9.913
11.098

Average
7.006
9.408
10.873
13.246
15.164
17.121
18.537
19.151
19.574
19.689

stdev
0.940
0.841
0.853
1.031
0.992
0.928
0.893
0.917
0.875
0.867

sterr
0.384
0.343
0.348
0.461
0.444
0.415
0.400
0.410
0.391
0.388

Encapsulated NGF Cumulative Release from 20 wt% PEG 3.4 kDa (units are ng if not specified)
Time (days)
0.08
0.17
0.33
0.50
1
2
7

Disk1
51.935
58.692
67.260
71.895
82.442
90.915
99.150

Disk2
36.486
42.814
53.337
57.090
66.230
73.011
84.321

Disk3
38.394
45.579
56.532
61.524
73.883
82.404
93.452

Disk4
45.570
50.085
59.154
62.573
70.117
79.877
83.963
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Disk5
50.052
54.687
66.188
69.416
77.984
88.627
104.395

Average
44.487
50.371
60.494
64.500
74.131
82.967
93.056

stdev
6.869
6.481
6.060
6.048
6.374
7.145
9.012

sterr
3.072
2.898
2.710
2.705
2.851
3.195
4.030

Encapsulated NGF Cumulative Release from 20 wt% PEG 3.4 kDa
Freeze-dried Sterilized Hydrogels (units are ng if not specified)
Time (days)
0.08
0.17
0.33
0.50
1
2
7

Disk1
3.099
3.913
4.601
4.962
5.698
6.862
7.416

Disk2
3.516
4.288
4.935
5.355
5.925
6.981
7.413

Disk3
2.897
3.520
4.375
4.843
5.454
6.446
6.990

Disk4
3.796
4.609
5.345
5.903
6.520
7.646
8.204

Disk5
2.873
3.663
4.149
4.361
5.258
5.970
6.298

Disk6
2.921
3.532
4.054
4.337
5.091
5.907
6.351

Average
3.184
3.921
4.576
4.960
5.658
6.635
7.112

stdev
0.385
0.444
0.493
0.601
0.517
0.663
0.725

sterr
0.157
0.181
0.201
0.245
0.211
0.271
0.296

Encapsulated NGF Cumulative Release from 30 wt% PEG 3.4 kDa (units are ng if not specified)
Time (days)
0.08
0.17
0.33
0.50
1
2
5
7

Disk1
32.542
35.012
37.468
39.738
42.763
46.834
50.782
52.329

Disk2
24.926
27.289
29.868
32.323
35.363
39.111
44.120
46.206

Disk3
26.542
28.874
31.098
33.262
36.978
40.265
45.858
47.929
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Disk4
20.772
22.628
24.437
26.308
30.255
33.818
39.274
41.714

Disk5
21.695
23.997
25.929
28.154
31.686
35.295
40.197
42.345

Average
25.295
27.560
29.760
31.957
35.409
39.065
44.046
46.105

stdev
4.680
4.857
5.104
5.215
4.924
5.088
4.643
4.345

sterr
2.093
2.172
2.283
2.332
2.202
2.275
2.077
1.943

Encapsulated NGF Cumulative Release from 10%(w/v) PEG 6kDa (units are ng if not specified)

Time (days)
0.08
0.17
0.33
0.50
1
2
5
7
10

Disk1
139.272
190.2
230.568
249.176
264.104
269.752
272.397
273.218
273.99

Disk2
153.192
204.12
248.648
269.816
285.416
291.224
293.805
294.706
295.542

Disk3
149.832
192.12
245.288
273.496
290.664
295.992
298.973
300.066
300.982

Disk4
145.032
196.44
242.888
265.176
284.744
296.312
300.093
301.202
302.038

Average
146.832
195.72
241.848
264.416
281.232
288.32
291.3168
292.2976
293.1384

stdev
6.051
6.178
7.882
10.715
11.721
12.595
12.907
13.032
13.079

sterr
3.025
3.089
3.941
5.358
5.861
6.298
6.454
6.516
6.539

Conjugated NGF Cumulative Release from 10%(w/v) PEG 6kDa (units are ng if not specified)

Time (days)
0.08
0.17
0.33
0.50
1
2
5
7
10
15

Disk1
120.078
157.245
197.807
223.559
274.967
288.935
297.244
299.408
301.397
302.634

Disk2
104.525
149.947
184.382
208.694
254.502
272.630
279.978
282.143
283.924
285.337

Disk3
99.047
126.296
159.636
179.868
210.796
223.004
229.088
230.837
232.234
233.471

Disk4
87.569
115.392
142.296
182.688
236.656
253.184
261.349
263.850
265.935
267.716
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Disk5
69.830
79.672
105.811
127.139
159.187
172.835
179.736
181.357
182.642
183.894

Average
96.210
125.710
157.986
184.390
227.222
242.118
249.479
251.519
253.226
254.610

stdev
18.825
30.855
36.241
36.830
44.753
45.855
46.455
46.727
47.030
47.090

sterr
8.419
13.799
16.207
16.471
20.014
20.507
20.776
20.897
21.032
21.059

Appendix 3

Cntrl (+)
10 ng/mL NGF

Cntrl (-) PEG 3.4kDa
Gels w/o NGF
supernatant

Cntrl (-)
RPMI-1640 w/o NGF

PC-12 exposed to hydrogels´ supernatants containing the released NGF. Scale bar = 100µm.
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4hrs release
NGF Encapsulated
30wt% PEG 3.4kDa

4hrs release
NGF Encapsulated
20wt% PEG 3.4kDa

Cntrl (+)
20 ng/mL NGF

Appendix 4
PEG : NGF Calculations
Encapsulated NGF
PEGda 3.4 kDa
Considering the dimensional swelling factor (DSF), original file dimensions d=4mm
Each disk has to contain 500ng NGF to release.
First, calculate the amount of solution required to create one disk.
(dimensions before swelling r = 2mm, h = 1mm):
V = r2h
V = mm2(1mm)
V = 12.57mm3 1cm3 1mL = 0.01257 mL
103 mm3 1cm3
This means, each disk is made with 0.01257mL of solution
Second, calculate the number of disks that 1mL of solution can make:
Theoretically, each mL can make up to: 1mL/0.01257mL = 79.58 disks.
Third, calculate the amount of NGF required for 1mL of solution to contain 500 ng NGF per
each 0.01257 mL (500ng NGF per disk):
500ng x 79.58 = 39,790ng ~ 40,000 ng
This means, 40,000 ng NGF are required in each mL of a 20% PEG sol’n



NGF was dissolved in RPMI-1640 media 100g in 100 L = [1,000,000 ng/mL]
20 wt% PEGda 3.4 kDa sol’n was prepared in PBS (pH=7.4) and 0.5% I-2959
C1V1 = C2V2
C1 = 1,000,000 ng/mL
C2 = 40,000 ng/mL
V2 = 1mL
V1 = ?

Conc. of the NGF aliquot
Desired final conc.
Final volume
mL of NGF sol’n required

V1 = (40,000 ng/mL) (1mL) = 0.04 mL
1L
1,000,000 ng/mL
1 x 10-3 mL




= 40L

Therefore, every 40L contains 40,000ng of NGF
40L of NGF sol’n were added to 1mL of a 20 % photocrosslinkable PEG sol’n.
Disks were built immediately. Hydrogells swell to final dimensions of 5mm in diameter,
containing 500 ng to release.
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Encapsulated NGF
PEGda 6 kDa
Dimensional swelling factor not considered. From a cured PEG layer, disks are stamped out
with dimensions of: d = 5 mm h = 1mm, each disk containing 500ng NGF to release:
Volume of a hydrogel disk:
V = r2h
V = mm2(1mm)
V = 19.63495 mm3 ~20 mm3
V = 19.64mm3

1cm3 1mL = 0.01964 mL = 19.64L
103 mm3 1cm3

There has to be 500ng per each 19.64 L of solution (500ng NGF per disk):
Theoretically, each mL can make up to: 1.0 mL/0.01964 mL = 51 disks.
500ng x 51 = 25.47 ng = 25.47 µL NGF sol’n.




100g NGF dissolved in 100 L RPMI-1640 + 1% BSA [1,000,000 ng/mL]
~ 25.47 L NGF sol’n per mL of a 6kDa PEGda sol’n
10% (w/v) PEGda 6kDa sol’n was prepared in PBS (pH=7.4) and DMPA/NVP
C1V1 = C2V2
C1 = 1,000,000 ng/mL
C2 = 25,465ng/mL
V2 = 1.0 mL
V1 = ?

Conc. of the NGF aliquot
Desired final conc.
Final volume
mL of NGF sol’n required

V1 = (25,465 ng/mL) (1.0 mL) = 0.02546 mL
1L
= 25.47L
1,000,000 ng/mL
1 x 10-3 mL



Therefore, every 25.47 L contains 25,465 ng of NGF
25.5 L of NGF sol’n added to 1.0 mL of a 10 % photocrosslinkable PEG sol’n.

Crosslinking a 10% 6kDa PEGda layer of 1mm thick, volume required?
Container d = 20.4mm
V = r2 h
V = (10.2mm)2 (1mm)
V = 326.85mm3
V = 326.85mm3
1 cm3 1mL = 0.326.85 mL = 326.85 L
103 mm3 1cm3
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Conjugated NGF (as determined 1:5 NGF to PEG ratio)
PEGda 3.4 kDa
1 mol PEG = 3400 Da
1 mol NGF = 26000 Da

Dalton = g/mol

Starting with the same 500ng NGF per 0.01257 mL PEG sol’n
Having to add the equal amount of 40,000 ng per mL of PEG sol’n
Taking 40,000ng NGF as the unit ratio
1 NGF : 5 PEG
40,000 ng NGF = 1
40,000 ng

1g
1 mol = 1.54 x 10-9mol
9
1x10 ng 26,000 g

(1.54 x 10-9mol) (5) = 7.69 x 10-9 mol PEG
7.69 x 10-9 mol PEG 3400g = 2.62 x 10-5 g PEG
1 mol
40,000 ng NGF : 2.62 x 10-5 g PEG
A stock solution of PEGda was prepared as follows:
0.004 4g PEG in 2 mL of PBS buffer previously prepared (pH = 8.55)
= [0.0022 g/mL] of PEG in PBS
The solution was syringe filtered.
C1V1 = C2V2
V1 = (2.62 x 10-5 g/mL) (1mL) = 0.0119mL
0.0022 g/mL
V1 = 12 L
An aliquot of 40L of NGF (containing 40,000 ng of the protein) was thawed.
12 L of the PEG were added to the NGF aliquot.
In addition, ~ 2mL of PBS (pH = 8.5) were also filtered and 48 L of this buffer were
added to the PEG-NGF to have a final vol of 100L and control over the pH to be basic,
since NGF was diluted in RPMI-1640 with a pH of 7.4.
The reaction was allowed to take place inside a 2mL siliconized vial covered with
aluminum foil incubated at room temperature for two hours.
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Conjugated NGF (as determined 1:5 NGF to PEG ratio)
PEG 6 kDa
1 mol PEG = 6000 Da
1 mol NGF = 26000 Da

Dalton = g/mol

Starting with the same 500ng NGF per 0.01964 mL PEG sol’n
Having to add the equal amount of 25,465 ng per 1.0 mL of PEG sol’n
Taking 25,465 ng NGF as the unit ratio
1 NGF : 5 PEG
1 NGF = 25,465 ng
25,465 ng

1g
1 mol = 9.79 x 10-10 mol NGF
9
1x10 ng 26,000 g

(9.79 x 10-10mol) (5) = 4.897 x 10-9 mol PEG
4.897 x 10-9 mol PEG 6000g = 2.94 x 10-5 g PEG
1 mol
25,465 ng NGF : 2.94 x 10-5 g PEG
A stock solution of PEGda 6kDa was prepared as follows:
0.001g PEG in 2.0 mL of PBS (pH = 7.43)
= [0.0005 g/mL] of PEG in PBS
The PEG in PBS solution was syringe filtered.
C1V1 = C2V2
C1 = 0.0005 g/mL
C2 = 2.94 x 10-5 g/mL
V2 = 1 mL
V1 = (2.94 x 10-5 g/mL) (1mL) = 0.0588 mL
0.0005 g/mL
V1 = 58.8 L




25.5 L NGF sol’n mixed with 58.8 L PEG stock sol’n
15.7 L added of a syringe filtered PBS buffer (pH = 7.4)
Allow to react inside a 2mL siliconized vial covered with aluminum foil at RT for 2
hrs
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